Use of the Fluid Challenge in Critically III Adult Patients: A Systematic Review

Antonio Messina, MD, PhD,* Federico Longhini, MD,† Corinne Coppo, MD,‡ Aline Pagni, MD,† Ramona Lungu, MD,‡ Chiara Ronco, MD,‡ Marco Ambrogio Cattaneo, MD,† Simone Dore, PhD,§ Giovanni Sotgiu, MD,§ and Paolo Navalesi, MD, FERS||

The fluid challenge (FC) aims at identifying patients in whom fluid administration improves hemodynamics. Although the FC has been extensively studied, the implementation and definition of improvement are not standardized. This systematic review of studies published between January 1, 1994 and December 31, 2014 characterizes these key components of the FC for critically ill adult patients, as described in the medical literature in the last 20 years. A literature search was performed using MEDLINE, Embase, and Cochrane. For each study, data were collected on study design, study size, study setting, patient population, and how the FC was administered. Eligibility criteria for FC were (1) the infusion of a definite quantity of fluid, (2) of a specific type, (3) in a fixed time period (expressed as either span or infusion rate), (4) with a defined hemodynamic variable as the target, and (5) for a predetermined threshold. One hundred fifty-seven full-text manuscripts were extracted from 870 potentially relevant studies. The inclusion criteria were met by 71 studies including 3617 patients. Sixty-six studies were from a single center and 45 were prospective observational in format. The most common amount infused was 500 cc, used by 55 (77.5%) studies. The most commonly infused fluids were colloids (62.0%). In 43 (60.5%) studies, the FC was administered between 20 and 30 minutes. A positive response to fluid administration was defined as an increase ≥15% of cardiac index or cardiac output in 44 (62.6%) studies. Static or dynamic physiologic indices were utilized in a minority of studies (16.9%) and safety limits for interrupting the FC are adopted in 4 (5.6%) studies only. This systematic review indicates that the FC most commonly consists in infusing 500 mL of crystalloids or colloids in 20-30 minutes, and considered an increase in cardiac index ≥15% as a positive response. However, definite standards for FC administration and evaluation remain undefined. (Anesth Analg 2017;125:1532-43)

ritically ill patients often receive fluids to increase blood pressure or cardiac output (CO) by increasing the cardiac stroke volume (SV).^{1,2} The fluid challenge (FC) is a diagnostic approach to hemodynamic management which aims at identifying the patients who respond to fluid administration with an increase in blood pressure or CO.³ In this way, the FC can identify patients for whom

Funding: None.

The authors declare no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.anesthesia-analgesia.org).

Potential conflicts of interest unrelated to the present study: Dr Navalesi's research laboratory has received equipment and grants from Maquet Critical Care, Draeger, and Intersurgical S.P.A. He also received honoraria/speaking fees from Maquet Critical Care, Draeger, Breas, Philips, Resmed and Hillrom. Dr Navalesi contributed to the development of the helmet Next, whose license for patent belongs to Intersurgical S.P.A., and receives royalties for that invention.

Reprints will not be available from the authors.

Address correspondence to Paolo Navalesi, MD, FERS, Anesthesia and Intensive Care, Department of Medical and Surgical Sciences, Magna Graecia University, Viale Europa – Loc. Germaneto, 88100, Catanzaro, Italia. Address e-mail: pnavalesi@unicz.it.

Copyright © 2017 International Anesthesia Research Society DOI: 10.1213/ANE.00000000002103

use of inotropes or vasopressors is the appropriate strategy. Therapeutically, a positive FC suggests that fluid administration should be continued as long as the response to FC is positive.⁴ The decision to stop fluid administration occurs when a negative response to FC occurs.

A patient is considered responsive to FC when hemodynamic improvement is observed after volemic expansion. While consensus exists on the use of FC to assess preload responsiveness,^{1,5} the type of fluid, extent and rate of administration, and hemodynamic targets (either variable and thresholds) are not standardized in clinical practice. Cecconi et al,¹ after reviewing the key components of the FC and its clinical use in the intensive care unit (ICU), proposed the infusion of a standard volume of 200 mL (or 3 mL/kg) in 5 minutes, while guidelines for ICU management of patients with severe sepsis and septic shock propose 500-1000 mL of crystalloids or 300-500 mL of colloids in 30 minutes.6 By affecting the extent of fluid responsiveness and hence the rate of responders, varying criteria for performing the FC and assessing the result FC may limit comparability among studies.

Two large observational studies indicate that both the mode of administration and assessment of the FC in the current clinical practice vary considerably between countries and over time.^{7,8} In particular, the 2015 FENICE trial, a recent prospective observational study performed in 311 ICUs located in 46 countries, found significant variability with respect to the amount and type of fluid and the rate of administration.⁸ To address this issue, we systematically reviewed existing literature to evaluate whether the FC in

November 2017 • Volume 125 • Number 5

From the *Anesthesia and Intensive Care Medicine, Maggiore della Carità University Hospital, Novara, Italy; †Anesthesia and Intensive Care Medicine, Sant'Andrea Hospital (ASL VC), Vercelli, Italy; ‡Department of Translational Medicine, Università del Piemonte Orientale "Amedeo Avogadro," Alessandria-Novara-Vercelli, Italy; §Clinical Epidemiology and Medical Statistics Unit, Department of Biomedical Sciences, University of Sassari, Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy; and IAnesthesia and Intensive Care, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy. Accepted for publication February 28, 2017.

Copyright © 2017 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.




Figure 1. Flow of the studies. FC indicates fluid challenge; ICU, intensive care unit.

critically ill patients is consistent among studies along the last 2 decades with respect to (a) amount and kind of fluid administration, (b) time of infusion, (c) hemodynamic variables and thresholds for fluid responsiveness, and (d) safety limits.

METHODS

Study Selection and Inclusion Criteria

For the purposes of this review, we defined FC as the infusion of a definite quantity of fluid of a specific quality in a fixed time (expressed as either span or infusion rate), and defined the outcome of the FC as a change in a defined hemodynamic variable for a predetermined threshold.

We included the following hemodynamic variables as potential indicators of a positive FC: CO, cardiac index (CI), SV, SV index (SVI), or surrogate SV estimations, ie, aortic velocity-time integrals and aortic blood flow, as assessed by either transthoracic or transoesophageal echocardiography. Only articles published in indexed scientific journals between January 1, 1994 and December 31, 2014 in the English language were considered. We selected studies enrolling more than 20 ICU patients receiving at least one FC. Reviews, case reports, and studies published in abstract form were not considered.

Search Strategy

Two authors (A.M. and F.L.) independently searched MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews using the following key words and their related MeSh terms: "fluid challenge," "fluid responsiveness," "stroke volume variation," "pulse pressure variation," "dynamic indices OR indexes," "passive leg raising," "inferior cava vein collapsibility," "systolic pressure variation." Included papers were also examined to

identify other studies of interest missed during the primary search.

Data Extraction

Pairs of examiners evaluated sets of 15–16 articles. The 2 members of each pair, who performed the evaluation independently from each other, extracted from the selected articles the following information using an ad hoc standardized form: study setting (type of study, geographical area and time period where and when the study was performed, and sample size), patient sample characteristics (gender, age, reason for admission, underlying diseases, ICU scores of gravity, mode of ventilation, and inotropic/vasopressor support), and criteria for hemodynamic instability.

When data from specific studies were not available, the corresponding authors were contacted to obtain missing information. In case of disagreement between the 2 examiners, the opinion of a third, senior, examiner was requested for a conclusive decision (P.N. or G.S.). The list of excluded articles was reported in Supplemental Digital Content, http://links.lww.com/AA/B745. Results were overall summarized qualitatively, owing to the between-study clinical and methodological heterogeneity.

Patients were divided into subgroups for analysis according to the primary cause of hemodynamic instability. We divided patients into 4 groups defined as: (1) septic, ie, systemic inflammatory response syndrome, sepsis, and septic shock, or conditions determining systemic inflammation (ie, pneumonia, pancreatitis, and abdominal infections), (2) postsurgical (postoperative patients without additional complications), (3) cardiac (patients with cardiogenic shock or recovering after cardiac arrest), (4) hypovolemic (trauma, nontraumatic hemorrhagic conditions, dehydration).

www.anesthesia-analgesia.org 1533

Copyright © 2017 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.

Table 1. Characteristics of the Studies Included In the Systematic Review Verter Monte Intervalue Autors Verter Policitation Study 1 nd Nome Michard et al ^{®1} 2003 36 Prospectivo observational study 1 nd Nome Finisse IF al ^{®1} 2004 39 Prospectivo observational study 1 nd Nome Situ ot al ^{®1} 2004 64 Prospectivo observational study 1 nd Nome Situ ot al ^{®1} 2004 24 Prospectivo observational study 1 nd Nome Nome ot al ^{®1} 2005 31 Prospectivo observational study 1 nd Nome Nome ot al ^{®1} 2005 71 Prospectivo observational study 1 nd Nome Natalini at al ^{®1} 2007 23 Prospectivo observational study 1 nd Nome Souther et al ^{®1} 2007 76 Prospectivo observational study 1 nd Nome Souther et al ^{®1} 20	Table 1 Characterist	ics of the Studies	Include	d in the Systematic Review			
Michard et all ^{BA} 2000 400 Prospective observational study 1 nd None Finisal et all ^{BA} 2004 39 Prospective observational study 1 nd None Silva et all ^{BA} 2004 24 Prospective observational study 1 nd None Silva et all ^{BA} 2004 24 Prospective observational study 1 nd None Valide et all ^{BA} 2005 51 Prospective observational study 1 nd None Valide et all ^{BA} 2005 71 Prospective observational study 1 nd None Valide et all ^{BA} 2006 72 Prospective observational study 1 nd None Valier all ^{BA} 2007 29 Prospective observational study 1 nd None Soubier ct all ^{BA} 2007 26 Prospective observational study 1 nd None Soubier ct all ^{BA} 2007 24 Prospective observational study 1 nd None				-		Months	Intervention
Michael et all ¹⁷ 2003 36 Prospective observational study 1 nd None Viailand Suron et all ¹⁶ 2004 66 Prospective observational study 1 nd Name Silva et all ¹⁶ 2004 21 Prospective observational study 1 nd Name Kramer et all ¹⁸ 2004 21 Prospective observational study 1 nd Name Monnet et all ¹⁶ 2005 38 Prospective observational study 1 nd Name Nornet et all ¹⁶ 2006 21 Prospective observational study 1 nd Name Nornet et all ¹⁶ 2007 59 Prospective observational study 1 nd Name Outrier et all ¹⁶ 2007 76 Prospective observational study 1 nd Name Outrier et all ¹⁶ 2007 76 Prospective observational study 1 nd Name Outrier et all ¹⁶ 2007 34 Nutilisentre interenvational study 1 nd				•			
Vielland Baron et al ¹⁴ 2004 66 Prospective observations study 1 nd None Krame et al ¹² 2004 21 Prospective observations study 1 nd None Valies et al ¹² 2005 38 Prospective observations study 1 nd None Monnet et al ¹⁶ 2005 38 Prospective observations study 1 nd None Prospective observations study 1 nd None Prospective observations study 1 nd None Prospective observations study 1 nd None Prospective observations study 1 nd None Souther et al ¹⁶ 2007 23 Prospective observations study 1 nd None Souther et al ¹⁶ 2007 76 Prospective observations study 1 nd Prospective observations study Ostron et al ¹⁶ 2007 24 Prospective observations study 1 nd Prospective observations study 1 nd None <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>							
Sink at R ^{IP} 2004 24 Prospective observations study 1 nd None Valide cit all ^{P1} 2005 51 Prospective observations study 1 nd None Monnet et all ^{P1} 2005 51 Prospective observations study 1 nd None Monnet et all ^{P1} 2006 71 Prospective observations study 1 nd None Aller et all ^{P1} 2006 20 Prospective observations study 1 nd None Solubiter et all ^{P1} 2007 23 Prospective observations study 1 nd None Solubiter et all ^{P1} 2007 76 Prospective observational study 1 nd None Lamia et all ^{P1} 2007 76 Prospective observational study 1 nd None Lamia et all ^{P1} 2007 32 Prospective observational study 1 nd None Lamia et all ^{P1} 2008 35 Prospective observational study 1 nd None	Feissel et al ²⁰	2004	39	Prospective observational study	1	nd	None
Ixamer ct all ¹⁹ 2004 2.1 Prospective observational study 1 n.d. Nome Monnet et all ¹⁶ 2005 3.8 Prospective observational study 1 n.d. Nome Monnet et all ¹⁶ 2006 2.2 Prospective observational study 1 n.d. None Natalini et all ¹⁶ 2006 2.2 Prospective observational study 1 n.d. None Feissel et all ¹² 2007 2.8 Prospective observational study 1 n.d. None Soubine et all ¹⁶ 2007 2.8 Prospective observational study 1 n.d. None Soubine et all ¹⁶ 2007 4.6 Prospective observational study 1 n.d. None Manna et all ¹⁶ 2007 4.6 Prospective observational study 1 n.d. None Malaci et all ¹⁷ 2008 2.0 Prospective observational study 1 n.d. None Malaci et all ¹⁶ 2009 2.8 Prospective observational study 1	Vieillard-Baron et al ⁵⁴	2004	66	Prospective observational study	1	nd	None
Valido cul all ¹⁰ 2005 5.1 Prospective observational study 1 n.d. Nome Monnel ot all ¹⁰ 2006 7.1 Prospective interventional study 1 n.d. None Monnel ot all ¹⁰ 2006 7.1 Prospective observational study 1 n.d. None Perner et all ¹⁸ 2006 3.0 Prospective observational study 1 n.d. None Southire of all ¹⁶ 2007 5.9 Prospective observational study 1 n.d. None Southire of all ¹⁶ 2007 7.6 Prospective observational study 1 n.d. None Monnet et all ¹⁸ 2007 7.6 Prospective observational study 1 n.d. None Maize et all ¹⁸ 2007 3.4 Prospective observational study 1 n.d. None Maize et all ¹⁸ 2007 3.4 Prospective observational study 1 n.d. None Maize et all ¹⁸ 2007 3.4 Prospective observational study 1	Silva et al ⁵⁰	2004	24	Prospective observational study	1	nd	None
Monnet et al 2006 38 Prospective observational study 1 nd None Natalini et al 2006 22 Prospective observational study 1 nd None Perse et al 2006 22 Prospective observational study 1 nd None Evise et al 2007 23 Prospective observational study 1 nd None Souther et al 2007 26 Prospective observational study 1 nd None Souther et al 2007 26 Retrospective observational study 1 nd None Monnet et al 2007 24 Prospective observational study 1 nd None Lamia et al 2007 32 Prospective observational study 1 nd None Marce t al 2007 32 Prospective observational study 1 nd None Jabbet et al 2007 32 Prospective observational study 1 nd None Valles et al		2004		Prospective observational study		nd	None
Monne tet all ⁶⁶ 2006 7.1 Prospective observational study 1 n.0 PLR Perner tal ⁶⁶ 2006 30 Prospective observational study 1 n.0 None Perner tal ⁶⁶ 2007 59 Prospective observational study 1 n.0 None Auler et all ⁶⁶ 2007 59 Prospective observational study 1 n.0 None Souther et all ⁶⁶ 2007 7.6 Prospective observational study 1 n.0 None Mannet tall ⁶⁶ 2007 7.6 Prospective observational study 1 n.0 None Maizel tall ⁶⁶ 2007 34 Multicentre interventional study 1 n.0 None Maizel tall ⁶⁷ 2003 22 Prospective observational study 1 n.0 None Mange Garcia et all ⁶¹ 2003 23 Prospective observational study 1 n.0 None Visitiana tall ⁶² 2003 24 Prospective observational study 1 None <							
Nataline is al ¹⁴ 2006 2.2 Prospective observational study 1 A None Feissel et al ¹⁷ 2007 2.3 Prospective observational study 1 nd None Soubirer et al ¹⁷⁶ 2007 2.3 Prospective observational study 1 nd None Soubirer et al ¹⁷⁶ 2007 2.6 Prospective observational study 1 nd None Osman et al ¹⁸⁶ 2007 2.6 Prospective observational study 1 nd None Lamia et al ¹⁸⁷ 2007 2.4 Prospective observational study 1 nd None Lamia et al ¹⁸⁷ 2007 3.4 Mitthertme interventional study 1 nd None Jabot ct al ¹⁶⁷ 2008 3.5 Prospective observational study 1 nd None Jabot ct al ¹⁶⁷ 2009 3.6 Prospective observational study 1 nd None Jabot ct al ¹⁶⁷ 2009 3.6 Prospective observational study 1 nd							
Permer tal ¹⁶ 2006 30 Prospective observational study 1 nd None Aufer et al ¹⁶ 2007 59 Prospective observational study 1 nd None Soubrier et al ¹⁷⁶ 2007 76 Prospective interventional study 1 nd None Comma et al ¹⁷⁶ 2007 76 Prospective interventional study 1 nd None Lamia et al ¹⁶⁰ 2007 76 Prospective interventional study 1 nd None Maize et al ¹⁷⁶ 2007 34 Multicontri interventional study 1 nd None Maize et al ¹⁷⁷ 2008 22 Prospective observational study 1 nd None Monge Garcia et al ¹⁷¹ 2008 30 Prospective observational study 1 nd None Vallee et al ¹⁶² 2009 38 Prospective observational study 1 nd None Vallee et al ¹⁶³ 2009 38 Prospective observational study 1 nd N							
Ficksel at all*120072.3Prospective observational study1ndNoneSoubrier et all*6200759Prospective interventional study1ndNoneSoubrier et all*6200796Retrospective study1ndNoneOmanet et all*1200776Prospective observational study1ndNoneLamia et all*6200724Prospective observational study1ndPLRWifels et all*6200732Prospective observational study1ndPLRWifels et all*6200732Prospective observational study1ndNoneJabot et all*6200835Prospective observational study1ndNoneJabot et all*6200836Prospective observational study1ndNoneValise et all*6200938Prospective observational study1ndNoneValise et all*6200938Prospective observational study1ndNoneNonge Garcia et all*6201032Prospective observational study1ndNoneNonge Garcia et all*6201032<							
Alter et al ¹⁶ 2007 59 Prospective observational study 1 6 None Soubire et al ¹⁶ 2007 76 Prospective observational study 1 38 None Monnet of al ¹⁶ 2007 76 Prospective observational study 1 nd None Maize of al ¹⁶ 2007 34 Multicontri interventional study 1 nd None Maize of al ¹⁶ 2007 34 Multicontri interventional study 1 nd None Maize of al ¹⁶ 2007 34 Multicontri interventional study 1 nd None Maize of al ¹⁶ 2008 32 Prospective observational study 1 nd None Monge Garcia et al ¹⁶ 2009 38 Prospective observational study 1 nd None Valide of al ¹⁶ 2009 36 Prospective observational study 1 nd None Malpub of al ¹⁶ 2010 24 Prospective observational study 1 nd None							
Soubier et al Parameter al Mornet et al Mornet							
Owner et al. ¹⁰ 2007 76 Prospective observational study 1 36 None Monnet et al. ¹⁰ 2007 76 Prospective observational study 1 nd None Maizel et al. ¹⁰ 2007 34 Multicentre interventional study 1 nd None Maizel et al. ¹⁰ 2008 22 Prospective observational study 1 nd None Jabot et al. ¹⁰ 2008 32 Prospective interventional study 1 nd None Jabot et al. ¹⁰ 2009 84 Prospective observational study 1 6 Valise et al. ¹⁰ Valise et al. ¹⁰ 2009 38 Prospective observational study 1 nd None Valise et al. ¹⁰ 2009 38 Prospective observational study 1 nd None Margub et al. ¹⁰ 2010 32 Prospective observational study 1 19 None Margub et al. ¹⁰ 2010 32 Prospective observational study 1 nd							
Osman et al ¹⁰ 2007 96 Retrospective study 1 nd None Lamia et al ⁶⁰ 2007 24 Prospective interventional study 1 nd PLR Maizel et al ⁶⁶ 2007 34 Mullicentre interventional study 1 8 None Wyffels et al ⁶⁶ 2008 22 Prospective observational study 1 nd PLR Monge Garcia et al ⁶¹⁰ 2008 30 Prospective interventional study 1 nd PLR Monge Garcia et al ⁶¹⁰ 2009 33 Prospective interventional study 1 24 None Visitisen et al ⁶¹⁶ 2009 33 Prospective observational study 1 nd None Mange Garcia et al ⁶¹² 2009 30 Prospective observational study 1 nd None Malpub et al ⁶¹⁴ 2010 34 Prospective observational study 1 nd None Malpub et al ⁶¹⁴ 2010 34 Prospective observational study 1 nd		2001	02		-	Ũ	
Monne tet al ⁸⁰ 2007 76 Prospective interventional study 1 nd None Maizel et al ⁸ 2007 34 Multicontre interventional study 1 nd PLR Maizel et al ⁸ 2007 34 Multicontre interventional study 1 nd None Maizel et al ⁸⁷ 2008 22 Prospective observational study 1 nd None Monge García et al ⁸⁷ 2008 30 Prospective interventional study 1 26 Valiashav maneuver Valide et al ⁸⁷ 2009 38 Prospective observational study 1 nd None Monge García et al ⁸⁷ 2009 38 Prospective observational study 1 12 None Malgude et al ⁸⁷ 2010 22 Prospective observational study 1 12 None Malgude et al ⁸⁷ 2010 22 Prospective observational study 1 12 None Malgude et al ⁸⁷ 2010 22 Prospective observational study 1 nd </td <td>Osman et al⁷⁸</td> <td>2007</td> <td>96</td> <td>Retrospective study</td> <td>1</td> <td>36</td> <td></td>	Osman et al ⁷⁸	2007	96	Retrospective study	1	36	
Naize Ict al ⁶⁷ 2007 34 Muticentre interventional study 1 nd PLR Vipfels et al ⁶⁷ 2008 22 Prospective observational study 1 nd None Jabot et al ⁶⁷ 2008 32 Prospective observational study 1 nd PLR Monge Garcia et al ⁶⁶ 2009 34 Prospective observational study 1 5 None Vallee et al ⁶⁵ 2009 38 Prospective observational study 1 nd None Monge Garcia et al ⁶⁶ 2009 38 Prospective observational study 1 nd None Mahjoub et al ⁶⁶ 2010 29 Prospective observational study 1 12 None Mahjoub et al ⁶⁶ 2010 32 Prospective observational study 1 nd None Lakhal et al ⁴¹ 2010 102 Muticontre interventional study 1 nd None Mahjoub et al ⁶⁶ 2011 33 Prospective observational study 1 nd N	Monnet et al ⁴⁰	2007	76		1	nd	None
Wyfels et all ⁶⁰ 2007 32 Prospective observational study 1 8 None Jabot et all ⁶² 2009 35 Prospective observational study 1 nd PLR Monge Garcia et all ⁶¹ 2008 30 Prospective observational study 1 24 None Visitsen et all ⁶² 2009 23 Prospective observational study 1 nd None Monge Garcia et all ⁶² 2009 36 Prospective observational study 1 nd None Bials et all ⁶² 2009 36 Prospective observational study 1 nd None Bials et all ⁶¹ 2010 29 Prospective observational study 1 12 None Heijmans et all ⁶¹ 2010 34 Prospective observational study 1 nd None Valoa et all ⁶¹ 2010 22 Prospective observational study 1 nd None Lakhal et all ⁶¹ 2011 30 Prospective observational study 1 nd	Lamia et al ⁶⁰	2007	24	Prospective interventional study	1	nd	PLR
Huang et al ⁷⁷ 2008 22 Prospective observational study 1 nd None Monge García et al ⁶¹ 2009 35 Prospective interventional study 1 6 Valiave maneuver Valie et al ⁶¹ 2009 30 Prospective observational study 1 5 None Valie et al ⁶¹ 2009 38 Prospective observational study 1 nd PLR Monge García et al ⁶² 2009 30 Prospective observational study 1 nd None Matioub et al ⁶⁶ 2009 35 Prospective observational study 1 12 None Matrit et al ⁶⁴ 2010 29 Prospective observational study 1 nd None Lakhal et al ⁶⁴ 2010 31 Prospective observational study 1 nd None Waler von Balimos et al ⁶⁷ 2010 32 Prospective observational study 1 nd None Maloub et al ⁶⁶ 2011 30 Prospective observational study 1 nd<	Maizel et al ⁹	2007	34	Multicentre interventional study	4	nd	PLR
Jabot at all ⁶² 2009 35 Prospective interventional study 1 nd PLR Monge Garcia et all ⁶³ 2009 84 Prospective observational study 1 6 Valaeva maneuver Vistisen et all ⁶² 2009 23 Prospective observational study 1 75 None Monge Garcia et all ⁶³ 2009 38 Prospective observational study 1 nd None Bials et all ⁶⁵ 2009 35 Prospective observational study 1 nd None Manjoub et all ⁶⁵ 2000 35 Prospective observational study 1 nd None Preau et all ⁴⁴ 2010 29 Prospective observational study 1 nd None Lupke et all ¹³ 2010 31 Prospective observational study 1 nd None Mahjoub et all ¹⁵ 2011 40 Prospective observational study 1 nd None Garad et all ¹³ 2011 40 Prospective observational study 1 nd	Wyffels et al56	2007		Prospective observational study	1	8	None
Nonge Garcia et al ¹⁴ 2008 30 Prospective interventional study 1 6 Valisabure maneuver Valle et al ¹⁶³ 2009 23 Prospective observational study 1 24 None Valle et al ¹⁶³ 2009 23 Prospective observational study 1 nd None Monge Garcia et al ¹⁶³ 2009 38 Prospective observational study 1 nd None Mahjoub et al ¹⁶⁴ 2010 29 Prospective observational study 1 nd None Moretti et al ¹⁶⁴ 2010 20 Prospective observational study 1 nd None Preau et al ¹⁶⁴ 2010 12 Multicentre interventional study 1 nd None Valer on Ballmoos et al ¹⁷⁵ 2010 22 Prospective observational study 1 nd None Mahjoub et al ¹⁶⁵ 2011 30 Prospective observational study 1 nd None Mahjoub et al ¹⁶⁵ 2011 373 Prospective observational study 1 </td <td>0</td> <td>2008</td> <td>22</td> <td>Prospective observational study</td> <td>1</td> <td>nd</td> <td>None</td>	0	2008	22	Prospective observational study	1	nd	None
Valide et all ⁵³ 2009 84 Prospective observational study 1 24 None Vistisen et all ⁵⁶ 2009 38 Prospective observational study 1 nd None Biais et all ⁶⁵ 2009 30 Prospective interventional study 1 nd None Biais et all ⁶⁵ 2009 35 Prospective observational study 1 12 None Manjoub et all ⁶⁵ 2010 29 Prospective observational study 1 19 PLR Hejimans et all ⁶⁴ 2010 34 Prospective observational study 1 nd None Presu et all ⁶⁴ 2010 31 Prospective observational study 1 nd None Majoub et all ⁶⁵ 2010 31 Prospective observational study 1 nd None Wijer von Ballmoos et all ⁶⁷ 2011 30 Prospective observational study 1 nd None Monnet et all ⁴³ 2011 25 Prospective observational study 1 8							
Visitisen et al ¹⁸ 2009 23 Prospective observational study 1 5 None Monge Garcia et al ⁸⁹ 2009 30 Prospective observational study 1 nd None Mahjoub et al ⁸⁵ 2009 30 Prospective observational study 1 26 None Mortiti et al ⁴⁶ 2010 92 Prospective observational study 1 nd None Preau et al ⁴⁶⁴ 2010 31 Prospective interventional study 1 nd None Mahjoub et al ⁸⁵ 2010 102 Multicentre interventional study 1 nd None Mahjoub et al ⁸⁵ 2010 22 Prospective observational study 1 nd None Loupee et al ⁸² 2011 37 Prospective observational study 1 nd None Machare-Delgado et al ⁸³ 2011 37 Prospective observational study 1 nd None Multer et al ⁶⁶ 2011 39 Prospective observational study 1 14	0						
Nonge Garcia et al ¹⁹ 2009 38 Prospective observational study 1 nd None Biais et al ¹⁶³ 2009 30 Prospective observational study 1 nd PLR Manjoub et al ¹⁶⁵ 2009 35 Prospective observational study 1 12 None Heijmans et al ¹⁶⁴ 2010 29 Prospective observational study 1 19 PLR Lakhal et al ¹⁶⁴ 2010 31 Prospective interventional study 1 6 PLR Lakhal et al ¹⁶⁴ 2010 31 Prospective interventional study 1 nd None Uope et al ¹⁶⁴ 2011 30 Prospective observational study 1 nd None Giraud et al ¹⁶² 2011 373 Prospective observational study 1 nd None Monet et al ¹⁶³ 2011 373 Prospective observational study 1 nd None Lakhal et al ¹²⁴ 2012 60 Prospective interventional study 1 14 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>							
Bials 2009 30 Prospective interventional study 1 nd PLR Mahjoub et al ³⁵ 2009 35 Prospective observational study 1 12 None Mahjoub et al ⁴⁶ 2010 29 Prospective observational study 1 19 None Heijman et al ⁴⁶ 2010 32 Prospective observational study 3 nd PLR Lakhal et al ⁴¹ 2010 102 Multicentre interventional study 1 nd None Vejer von Ballmoos et al ⁸⁷ 2010 22 Prospective observational study 1 nd None Giraud et al ⁴³ 2011 30 Prospective observational study 1 nd None Machare-Delgado et al ⁴³ 2011 373 Prospective observational study 1 14 None Machare-Delgado et al ⁴³ 2011 65 Multicenter observational study 1 14 None Machare-Delgado et al ⁴³ 2012 60 Prospective observational study 1 1							
Nahipub et al ⁸⁵ 2009 35 Prospective observational study 1 6 None Moretti et al ⁸⁴ 2010 29 Prospective observational study 1 12 None Preau et al ⁸⁴ 2010 34 Prospective observational study 1 19 PLR Lakhal et al ¹⁴ 2010 34 Prospective interventional study 1 6 PLR Maljoub et al ⁸⁶ 2010 31 Prospective interventional study 1 6 PLR Wyler von Ballmoos et al ⁸⁷ 2011 40 Prospective observational study 1 nd None Giraud et al ⁵² 2011 30 Prospective observational study 1 nd None Machare-Delgato et al ⁸³ 2011 25 Prospective observational study 1 18 None Muller et al ⁶⁶ 2011 39 Prospective observational study 1 14 None Muller et al ⁶⁶ 2012 40 Prospective interventional study 1 nd	0						
More til et al ⁶⁶ 2010 29 Prospective observational study 1 12 None Heijman et al ⁶⁶ 2010 34 Prospective interventional study 1 19 PLR Lakhal et al ¹⁴ 2010 102 Multicentre interventional study 3 nd PLR Maljoub et al ⁶⁵ 2010 22 Prospective interventional study 1 nd None Wyler von Ballmoos et al ⁵⁷ 2011 40 Prospective observational study 1 nd None Giraud et al ⁶⁵ 2011 30 Prospective observational study 1 nd None Machare-Dejdad et al ¹³³ 2011 25 Prospective observational study 1 nd None Lakhal et al ⁶⁶ 2011 39 Prospective observational study 1 14 None Lakhal et al ¹⁶⁹ 2012 112 Multicentre interventional study 1 nd None Monnet et al ⁶⁶ 2012 42 Prospective observational study 1 nd </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Heijmans et al ²⁶ 2010 92 Prospective observational study 1 nd None Preau et al ⁶⁴ 2010 34 Prospective interventional study 1 19 PLR Mahjoub et al ⁶⁵ 2010 31 Prospective interventional study 1 6 PLR Wyler von Ballmoos et al ⁶⁷ 2010 22 Prospective observational study 1 nd None Giraud et al ⁶⁸ 2011 30 Prospective observational study 1 nd None Giraud et al ⁶⁹ 2011 37 Prospective observational study 1 nd None Mahonet et al ⁴¹³ 2011 25 Prospective observational study 1 14 None Muller et al ⁶⁶ 2011 39 Prospective observational study 1 14 None Lakhal et al ¹²⁰ 2012 42 Prospective observational study 1 14 None Muller et al ⁶⁷ 2012 42 Prospective observational study 1 nd None Muller et al ⁶⁷ 2012 42 Prospective observa							
Preau et al ⁶⁴ 2010 34 Prospective interventional study 1 19 PLR Lakhal et al ¹¹ 2010 102 Multicentre interventional study 3 nd PLR Maljoub et al ⁶⁵ 2010 31 Prospective interventional study 1 nd None Oupce et al ¹²¹ 2011 30 Prospective observational study 1 nd None Giraud et al ⁶⁵ 2011 373 Prospective observational study 1 nd None Machare-Delgado et al ⁶³ 2011 25 Prospective observational study 3 18 None Lakhal et al ⁶⁴ 2012 60 Prospective observational study 1 14 None Muller et al ⁶⁶ 2012 122 Prospective observational study 1 nd None Muller et al ⁶⁷ 2012 412 Prospective observational study 1 nd None Muller et al ⁶⁷ 2012 42 Prospective observational study 1 nd							
Lakhal et al ¹⁴¹ 2010 102 Multicentre interventional study 3 nd PLR Mahjoub et al ^{65 2010 31 Prospective observational study 1 6 PLR Mone Loupec et al^{57 2010 22 Prospective observational study 1 nd None Comparison None Comparison Compariso}}							
Mahjoub et al ⁸⁵ 2010 31 Prospective interventional study 1 6 PLR Wyler von Ballmoos et al ⁵⁷ 2010 22 Prospective observational study 1 nd None Giraud et al ²⁵ 2011 30 Prospective observational study 1 nd None Monnet et al ⁴³ 2011 373 Prospective observational study 1 nd None Machare-Delgado et al ⁵³ 2011 25 Prospective observational study 3 18 None Multer et al ⁵⁶ 2011 65 Multicenter observational study 1 14 None Multer et al ⁵⁶ 2012 60 Prospective observational study 1 14 None Khwannimit et al ²⁹ 2012 42 Prospective observational study 1 nd None Monnet et al ⁷⁴ 2012 38 Prospective observational study 1 nd PlcR; EEO Multer et al ⁴⁷ 2012 40 Prospective observational study 1 24<							
Wyer von Ballmoos et al201022Prospective observational study1ndNoneLoupee et al201140Prospective observational study1ndNoneGiraud et al201130Prospective observational study1ndNoneMonnet et al2011373Prospective observational study1ndNoneMachare-Delgado et al201125Prospective observational study18NoneLakhal et al201139Prospective observational study111100 mL FC testYazigi et al201260Prospective observational study114NoneLakhal et al201212Multicente interventional study1ndNoneMonnet et al2012201242Prospective observational study1ndNoneMonnet et al201238Prospective observational study1ndNoneMonnet et al201242Prospective observational study1ndNoneMonnet et al201238Prospective observational study1ndNoneMonnet et al201240Prospective observational study1ndNoneMulte et al201240Prospective observational study1ndNoneMonnet et al201240Prospective observational study1ndNoneMulte et al201247Prospective observation							
Loupec et al Giraud et al (1)201140Prospective observational study1ndNoneGiraud et al (1)201130Prospective observational study1ndNoneMonnet et al (1)201125Prospective observational study1ndNoneMachare-Delgado et al (1)201125Prospective observational study111100 mLFC testMachare-Delgado et al (1)2012112Multicenter observational study114NoneMuller et al (1)2012112Multicentre interventional study1ndNoneVazigi et al (1)2012112Multicentre interventional study1ndNoneKhwannimit et al (10)201212288Prospective observational study1ndNoneMonnet et al (1)201254Prospective observational study1ndNoneMonnet et al (1)201224Prospective observational study1ndNoneMonnet et al (1)201224Prospective observational study1ndNoneMuller et al (1)201224Prospective observational study1ndNoneMonnet et al (1)201237Prospective observational study1ndNoneMonnet et al (1)201237Prospective observational study1ndNoneMonge Garcia et al (1)201235							
Monnet et al ⁴³ 2011 373 Prospective observational study 1 nd None Machare-Delgado et al ⁶³ 2011 25 Prospective observational study 1 8 None Lakhal et al ⁴² 2011 65 Multicenter observational study 1 11 100 mL FC test Yazig et al ⁶⁶ 2012 60 Prospective observational study 1 14 None Lakhal et al ¹⁰ 2012 12 Multicentre interventional study 1 nd None Monnet et al ¹⁴⁴ 2012 38 Prospective observational study 1 nd None Monnet et al ¹⁷¹ 2012 54 Prospective observational study 1 nd None Preau et al ⁶⁸ 2012 23 Prospective observational study 1 24 None Malier et al ¹⁷⁴ 2012 83 Prospective interventional study 1 24 None Monge Garcia et al ¹⁶⁹ 2012 37 Prospective observational study 1 nd <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	-						
Machare-Delgado et al201125Prospective observational study18NoneLakhal et al201165Multicenter observational study318NoneYazigi et al201139Prospective interventional study111100 mL FC testYazigi et al201260Prospective observational study114NoneLakhal et al2012112Multicentre interventional study318PLRKhwannimit et al201242Prospective observational study1ndNoneMonnet et al112201254Prospective observational study1ndNoneMonnet et al2012201240Prospective interventional study124NoneMuller et al2012201223Prospective interventional study124NoneMonnet et al201223Prospective interventional study11PLR; EEOMuller et al201237Prospective interventional study1124Monge Garcia et al201237Prospective interventional study11NoneDong et al201237Prospective interventional study118PLRBiais et al201225Prospective interventional study118PLRCong et al201225Prospective observational study14NoneSuehiro et al201226<	Giraud et al ²⁵	2011	30	Prospective observational study	1	nd	None
Lakhal et al12201165Multicenter observational study318NoneMuller et al66201139Prospective interventional study111100 mL FC testYazigi et al58201260Prospective observational study114NoneLakhal et al102012112Multicentre interventional study318PLRKhwannimit et al59201242Prospective observational study1ndNoneMonnet et al44201238Prospective observational study1ndNoneMonnet et al47201240Prospective observational study1ndPLR; EEOMuller et al47201240Prospective observational study112Deep inspirationmaneuvermaneuvermaneuvermaneuvermaneuvermaneuverMaljoub et al54201247Prospective observational study1ndPLR; EEOMonnet et al74201237Prospective interventional study1ndNoneMonge Garcia et al69201237Prospective interventional study1ndNoneBiais et al77201225Prospective interventional study18NoneCecconi et al46201231Prospective observational study14NoneSuehiro et al44201340Prospective observational study16NoneFellahi et al67201225Prospe	Monnet et al ⁴³	2011	373	Prospective observational study	1	nd	None
Muller et al ⁶⁶ 2011 39 Prospective interventional study 1 11 100 mL FC test Yazigi et al ⁸⁸ 2012 60 Prospective observational study 1 14 None Lakhal et al ¹⁰ 2012 112 Multicentre interventional study 1 nd None Khwannimit et al ²⁹ 2012 42 Prospective observational study 1 nd None Monnet et al ⁴¹ 2012 54 Prospective observational study 1 nd None Muller et al ⁶⁷ 2012 40 Prospective observational study 1 24 None Preau et al ⁶⁸ 2012 23 Prospective observational study 1 24 None Mallor et al ⁶⁴ 2012 83 Prospective observational study 1 nd PLR: EEO Monnet et al ⁷⁴ 2012 37 Prospective interventional study 1 nd None Jong Garcia et al ⁶⁹ 2012 35 Prospective interventional study 1 8	Machare-Delgado et al ³³	2011	25	Prospective observational study	1	8	None
Yazigi et al Pazigi et al201260Prospective observational study114NoneLakhal et al Lakhal et al Pasigi et al2012112Multicentre interventional study318PLRKhwannimit et al Pasigi et al201242Prospective observational study1ndNoneMonnet et al Monnet et al Preau et al Preau et al201254Prospective observational study1ndPLR; EEOMuller et al Preau et al <td></td> <td>2011</td> <td>65</td> <td>Multicenter observational study</td> <td></td> <td>18</td> <td>None</td>		2011	65	Multicenter observational study		18	None
Lakhal et al102012112Multicentre interventional study318PLRKhwannimit et al129201242Prospective observational study1ndNoneMonnet et al44201238Prospective observational study1ndNoneMonnet et al71201254Prospective observational study1ndPLR; EEOMuller et al47201240Prospective observational study124NonePreau et al68201223Prospective observational study124NoneMahjoub et al34201283Prospective observational study124NoneMonnet et al74201277Prospective interventional study1ndPLR; EEOMonge Garcia et al69201237Prospective interventional study1ndNoneDong et al70201225Prospective observational study1ndNoneFellahi et al67201225Prospective observational study14NoneSuehiro et al14201280Prospective observational study16NoneFellahi et al67201331Prospective observational study18NoneSuehiro et al14201280Prospective observational study18NoneSuehiro et al14201280Prospective observational study19NoneSuehiro et al14201231Prospective							
Khwannimit et al201242Prospective observational study1ndNoneMonnet et al201238Prospective observational study1ndNoneMonnet et al201254Prospective interventional study1ndPLR; EEOMuller et al201224Prospective observational study124NonePreau et al201223Prospective observational study124NoneMahjoub et al201223Prospective observational study124NoneManoet et al201247Prospective interventional study124NoneMonge Garcia et al201237Prospective interventional study1ndPLR; EEOMonge Garcia et al201235Prospective interventional study1ndNoneDong et al201225Prospective interventional study118PLRFellahi et al201225Prospective observational study16NoneSuehiro et al201340Prospective observational study19NoneSuehiro et al201331Prospective observational study110PLRFischer et al201335Prospective observational study18NoneLakhal et al30Multicenter observational study18NoneSuehiro et al201335Prospective observational study18<	-						
Monnet et al201238Prospective observational study1ndNoneMonnet et al201254Prospective interventional study1ndPLR; EEOMuller et al201220Prospective observational study124NonePreau et al88201223Prospective interventional study124NoneMahjoub et al201283Prospective observational study124NoneMonnet et al201283Prospective interventional study1ndPLR; EEOMonnet et al201237Prospective interventional study1ndPLR; EEOMonge Garcia et al201237Prospective interventional study1ndNoneDong et al201235Prospective interventional study1ndNoneFellahi et al67201225Prospective interventional study118PLRFellahi et al201225Prospective observational study14NoneSuehiro et al201340Prospective observational study110PLRFischer et al201331Prospective observational study18NoneSaugel et al201335Prospective observational study18NoneLakhal et al201335Prospective observational study18NoneSaugel et al201335Prospective observatio							
Monnet et al201254Prospective interventional study1ndPLR; EEOMuller et al2012201240Prospective observational study124NonePreau et al88201223Prospective interventional study124NoneMahjoub et al34201283Prospective observational study124NoneMonnet et al201247Prospective interventional study1ndPLR; EEOMonge Garcia et al69201237Prospective interventional study15PLRBiais et al201235Prospective interventional study1ndNoneDong et al201225Prospective interventional study118PLRFellahi et al201225Prospective observational study14NoneCecconi et al14201280Prospective observational study14NoneCecconi et al201340Prospective observational study16NoneFreitas et al201331Prospective observational study110PLRFischer et al201335Prospective observational study18NoneLakhal et al201335Prospective observational study18NoneKupersztych-Hagege et al201335Prospective observational study18NoneKupersztych-Hagege et al							
Muller et al201240Prospective observational study124NonePreau et al201223Prospective interventional study112Deep inspiration maneuverMahjoub et al344201283Prospective observational study124NoneMonnet et al201283Prospective interventional study124NoneMonge Garcia et al201247Prospective interventional study1ndPLR; EEOBiais et al201237Prospective interventional study1ndNoneDong et al201232Prospective interventional study118PLRFellahi et al201225Prospective interventional study16PLRFellahi et al201225Prospective observational study18NoneCecconi et al201280Prospective observational study16NoneFreitas et al201231Prospective observational study119NoneSaugel et al75201331Prospective observational study110PLRFischer et al201387Prospective observational study18NoneLakhal et al201335Prospective observational study18NoneKupersztych-Hagege et al201335Prospective observational study1NoneKupersztych-Hagege et al201348 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Preau et al68201223Prospective interventional study112Deep inspiration maneuverMahjoub et al34201283Prospective observational study124NoneMonnet et al74201247Prospective interventional study1ndPLR; EEOMonge Garcia et al69201237Prospective interventional study15PLRBiais et al17201235Prospective interventional study118PLRDong et al70201225Prospective interventional study16PLRFellahi et al67201225Prospective observational study14NoneSuehiro et al14201280Prospective observational study18NoneCecconi et al18201231Prospective observational study119NoneSaugel et al75201331Prospective observational study110PLRFischer et al24201335Prospective observational study110PLRLakhal et al132013130Multicenter observational study110NoneMonnet et al41201335Prospective observational study110NoneKupersztych-Hagege et al72201351Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective observational study1ndNone							
Mahjoub et al34201283Prospective observational study124NoneMonnet et al74201247Prospective interventional study1ndPLR; EEOMonge Garcia et al ⁶⁹ 201237Prospective interventional study15PLRBiais et al ¹⁷ 201235Prospective observational study1ndNoneDong et al ⁷⁰ 201232Prospective interventional study118PLRFellahi et al ⁶⁷ 201225Prospective interventional study16PLRFellahi et al ⁶⁷ 201225Prospective observational study14NoneSuehiro et al ¹⁴ 201280Prospective observational study18NoneCecconi et al ¹⁸ 201231Prospective observational study119NoneSaugel et al ⁷⁵ 201331Prospective observational study110PLRFischer et al ²⁴ 201387Prospective observational study18NoneLakhal et al ¹³ 2013130Multicenter observational study318NoneMonnet et al ⁴¹ 201335Prospective observational study1ndNoneKupersztych-Hagege et al ⁷² 201348Prospective observational study1ndNone							
Mahjoub et al34201283Prospective observational study124NoneMonnet et al74201247Prospective interventional study1ndPLR; EEOMonge Garcia et al ⁶⁹ 201237Prospective interventional study15PLRBiais et al ¹⁷ 201235Prospective observational study1ndNoneDong et al70201232Prospective interventional study118PLRFellahi et al67201225Prospective interventional study14NoneSuehiro et al14201280Prospective observational study18NoneCecconi et al18201231Prospective observational study16NoneSaugel et al75201340Prospective interventional study119NoneSaugel et al15201331Prospective observational study110PLRFischer et al24201387Prospective observational study18NoneLakhal et al132013130Multicenter observational study18NoneMonnet et al42201351Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective observational study1ndNone					-		
Monnet et al201247Prospective interventional study1ndPLR; EEOMonge Garcia et al201237Prospective interventional study15PLRBiais et al201235Prospective observational study1ndNoneDong et al201232Prospective interventional study118PLRFellahi et al6PLRFellahi et al201225Prospective interventional study14NoneSuehiro et al201225Prospective observational study18NoneSuehiro et al201231Prospective observational study16NoneCecconi et al201231Prospective observational study16NoneSaugel et al201340Prospective observational study119NoneSaugel et al201331Prospective observational study110PLRFischer et al201387Prospective observational study18NoneLakhal et al201335Prospective observational study318NoneMonnet et al201351Prospective observational study1ndNoneKupersztych-Hagege et al201348Prospective observational study1ndNone	Mahjoub et al ³⁴	2012	83	Prospective observational study	1	24	
Biais et al17201235Prospective observational study1ndNoneDong et al70201232Prospective interventional study118PLRFellahi et al67201225Prospective interventional study16PLRFellahi et al22201225Prospective observational study14NoneSuehiro et al14201280Prospective observational study18NoneCecconi et al18201231Prospective observational study16NoneFreitas et al15201340Prospective observational study119NoneSaugel et al75201331Prospective observational study110PLRFischer et al24201387Prospective observational study18NoneLakhal et al132013130Multicenter observational study318NoneMonnet et al41201335Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective interventional study1ndPLR	-						PLR; EEO
Dong et al70201232Prospective interventional study118PLRFellahi et al67201225Prospective interventional study16PLRFellahi et al22201225Prospective observational study14NoneSuehiro et al14201280Prospective observational study18NoneCecconi et al18201231Prospective observational study16NoneFreitas et al15201340Prospective observational study119NoneSaugel et al75201331Prospective observational study110PLRFischer et al24201387Prospective observational study18NoneLakhal et al132013130Multicenter observational study318NoneMonnet et al41201335Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective interventional study1ndPLR	Monge Garcia et al ⁶⁹	2012	37	Prospective interventional study	1	5	PLR
Fellahi et al67201225Prospective interventional study16PLRFellahi et al22201225Prospective observational study14NoneSuehiro et al14201280Prospective observational study18NoneCecconi et al18201231Prospective observational study16NoneFreitas et al15201340Prospective observational study119NoneSaugel et al75201331Prospective observational study110PLRFischer et al24201387Prospective observational study18NoneLakhal et al132013130Multicenter observational study318NoneMonnet et al41201335Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective interventional study1ndPLR	Biais et al ¹⁷	2012	35	Prospective observational study	1	nd	None
Fellahi et al201225Prospective observational study14NoneSuehiro et al201280Prospective observational study18NoneCecconi et al201231Prospective observational study16NoneFreitas et al201340Prospective observational study119NoneSaugel et al201331Prospective observational study110PLRFischer et al201387Prospective observational study18NoneLakhal et al2013130Multicenter observational study318NoneMonnet et al201335Prospective observational study1ndNoneKupersztych-Hagege et al201348Prospective interventional study1ndPLR	Dong et al ⁷⁰			Prospective interventional study	1		
Suehiro et al14201280Prospective observational study18NoneCecconi et al18201231Prospective observational study16NoneFreitas et al15201340Prospective observational study119NoneSaugel et al75201331Prospective interventional study110PLRFischer et al24201387Prospective observational study18NoneLakhal et al132013130Multicenter observational study318NoneMonnet et al41201335Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective interventional study1ndPLR							PLR
Cecconi et al18201231Prospective observational study16NoneFreitas et al15201340Prospective observational study119NoneSaugel et al75201331Prospective interventional study110PLRFischer et al24201387Prospective observational study18NoneLakhal et al132013130Multicenter observational study318NoneMonnet et al41201335Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective interventional study1ndPLR							
Freitas et al15201340Prospective observational study119NoneSaugel et al75201331Prospective interventional study110PLRFischer et al24201387Prospective observational study18NoneLakhal et al132013130Multicenter observational study318NoneMonnet et al41201335Prospective observational study1ndNoneMonnet et al42201351Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective interventional study1ndPLR							
Saugel et al75201331Prospective interventional study110PLRFischer et al24201387Prospective observational study18NoneLakhal et al132013130Multicenter observational study318NoneMonnet et al41201335Prospective observational study1ndNoneMonnet et al42201351Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective interventional study1ndPLR							
Fischer et al24201387Prospective observational study18NoneLakhal et al132013130Multicenter observational study318NoneMonnet et al41201335Prospective observational study1ndNoneMonnet et al42201351Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective interventional study1ndPLR							
Lakhal et al132013130Multicenter observational study318NoneMonnet et al41201335Prospective observational study1ndNoneMonnet et al42201351Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective interventional study1ndPLR	-						
Monnet et al201335Prospective observational study1ndNoneMonnet et al201351Prospective observational study1ndNoneKupersztych-Hagege et al201348Prospective interventional study1ndPLR							
Monnet et al42201351Prospective observational study1ndNoneKupersztych-Hagege et al72201348Prospective interventional study1ndPLR							
Kupersztych-Hagege et al201348Prospective interventional study1ndPLR							
				· · · · · · · · · · · · · · · · · · ·			
	Monnet et al ⁷³	2013	65	Prospective interventional study	1	nd	PLR

(Continued)

1534www.anesthesia-analgesia.orgANESTHESIA & ANALGESIACopyright © 2017 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.

Table 1. Continued						
Authors	Year of Publication	Patients	Study	Centers	Months	Intervention
Luzi et al ³²	2013	52	Prospective observational study	1	4	None
Fischer et al ²³	2013	45	Prospective observational study	1	6	None
Marik et al ³⁶	2013	34	Prospective observational study	1	9	PLR
Smorenberg et al ⁵¹	2013	32	Prospective observational study	1	nd	None
Hu et al ⁷⁹	2013	63	Retrospective study	1	24	None
Ishihara et al ²⁸	2013	43	Prospective observational study	1	nd	None
Charbonneau et al19	2014	44	Prospective observational study	1	11	None
Wu et al ⁷⁷	2014	50	Prospective interventional study	1	8	10 second FC test

Abbreviations: EEO, end-expiratory occlusion test; FC, fluid challenge; nd, not defined; PLR, passive leg raising.

We also assessed the relationship between rates of FC that exceeded the average response of the overall studies and primary reason for hemodynamic instability (see above); the 2 most common criteria for indicating FC administration; and modalities of FC delivery (type of fluid and rate of administration).

Statistical Analysis

Statistical analysis was conducted on the summary statistics described in the selected articles (eg, means, medians, proportions) and, therefore, the statistical unit of observation for all the selected variables was the single study and not the patient. No meta-analyses on summary findings or on individual patient data were performed.

Descriptive statistics of individual studies used different statistical indicators for central tendency and variability, such as means and standard deviations (SD; ie, age, tidal volume, fluid responders, severity scores), whereas absolute and relative frequencies were adopted for qualitative variables. To show 1 single indicator for the quantitative variables we collected, means with SD or medians and interquartile ranges (IQR) were used, as appropriate.

Student *t* test or Mann-Whitney *U* test in case of parametric or nonparametric distributions, respectively, were used to assess a difference of mean values between responders and nonresponders.

A logistic regression was performed using summary statistics displayed in the selected articles with the scope of assessing the relationship between a proportion of responders higher than 52% (ie, average proportion of responders; we dichotomized the variable for the logistic regression purposes) and several independent covariates (ie, hemodynamic instability, oliguria, hypotension, type of fluid, and rate of administration).

The statistical software STATA13 (StataCorp, College Station, TX) was used to perform all the computations.

RESULTS

The electronic search identified 870 potentially relevant studies. Detailed description of the selection process flow is provided in Figure 1. After evaluating 157 full-text manuscripts, the inclusion criteria were met by 71 studies, none published before 2000. Five of the 157 (3.1%) studies required revision by senior examiners because of disagreement between the coupled examiners. We did not find any further relevant publications by reviewing the bibliography of the selected studies.

Study Design

Of the 71 studies included, 5 were multicentered (3 interventional⁹⁻¹¹ and 2 observational^{12,13}), while 64 were

single-centered (45 prospective observational,^{14–58} 19 prospective interventional,^{59–77} and 2 retrospective^{78,79} (Table 1). The median (IQR) of the mean duration of the studies was 9.0 (6.0–18.0) months; 60 of them (83.1%) were performed in a university hospital and 59 (81.7%) in European countries.

Characteristics of the Population Enrolled

Overall, the 71 studies include 3617 patients, with a median (IQR) of 38 (31–59) per study. The median (IQR) of the mean patient age across studies was 61.0 (58.5–65.0) years overall, 25 (7–40) for patients with septic shock, 26 (16–32) for surgical 14 (7–18) for patients with cardiogenic shock, 6 (5–12) for patients with hypovolemic shock, 6 (4–11) for trauma patients, and 3 (2–5) for patients with hemorrhagic shock. The median (IQR) of the mean number of FCs administered was 39 (32–68).

Ten studies did not report gender.^{21,26,33,41,47,48,55,57,65,74} Thirty-two studies^{16–18,20–28,30,36–41,45,46,51,55,56,58–60,63,67,75,76,78} did not report any severity of illness scores at ICU admission. Of the remaining 39 studies, in 9 studies the median (IQR) of the mean reported sepsis-related organ failure assessment score was 10.5 (9.0–12.0),^{14,15,29,31,33,48–50,57} in 10 the median (IQR) of the mean reported acute physiology and chronic health evaluation score was 19.0 (17.0– 23.0),^{15,29,47,50,61,66,69,70,77,79} and in 27 the median (IQR) of the mean a simplified acute physiology score was 55.0 (47.0–57.5).^{9–13,19,31,32,34,35,42–44,48,52–54,57,62,64–66,68,71–74,76}

Twenty-four studies (33.8%) did not report the use of vasopressors or inotropes.^{9,15,16,18,20,26–28,32,36,47,48,55–58,63–65,68,70,76,77,79} In the remaining studies, norepinephrine was the most common (44/47, 93.6%), at a dose of 0.4 (0.2–0.7) μ g/kg/min, followed by dobutamine (26/47, 55.3%), at 7.1 (6.0–8.0) μ g/kg/min, dopamine (13/47, 27.7%) at 7.5 (5.0–10.0) μ g/kg/min, and epinephrine (10/47, 21.3%) at 0.4 (0.15–0.55) μ g/kg/min (median of the mean dose of drug reported across the studies).

The mode of ventilation was not specified in 10 (14.1%) studies,^{10,13,18,21,37,44,50,52,77,79} while 6 (8.5%) enrolled only breathing patie spontaneously nts.^{9,47,61,64,68,76} Thirty-nine (55.0%) studies included patients receiving volume-targeted controlled ventilation, 11, 12, 15–17, 19, 20, 22–26, 28–31, 34–36, 38, 41, 45–48, 51, 53, 54, 56–58, 65, 67, 69, 70, 72–74, 78 with the median (IQR) of the mean tidal volume across studies of 7.4 (6.5-8.1) mL/kg. One (1.4%) included patients receiving pressure-targeted controlled ventilation.27 Two (2.8%) studies enrolled patients undergoing volume-targeted assist/control,^{33,71} 1 (1.4%) pressure support,⁴⁹ and 1 (1.4%) airway pressure release ventilation.¹⁴ The remaining studies enrolled a mixed population of patients spontaneously breathing or mechanically ventilated. 32,40,42,43,59,60,62,63,75

www.anesthesia-analgesia.org 1535

Table 2. Indications for Fluid Challenge Administration

					Indications for FC				
						Need or Reduction		Diagnosis of	Renal or
Authors	Hypotension	Oliguria	Skin Mottling	Tachycardia	Physician	of Inotropes or Vasopressors	Lactate Increase	Sepsis or Septic Shock	Hepatic Dysfunction
Michard et al ³⁸		-	No	No	No	Yes	No	Yes	•
Michard et al ³⁷	Yes No	No No	No	No	Yes	No	No	No	No No
Feissel et al ²⁰	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes
Vieillard-Baron et al ⁵⁴	Yes	No	No	No	No	Yes	No	Yes	No
Silva et al ⁵⁰	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No
Kramer et al ³⁰	No	No	No	No	No	No	No	No	No
Vallée et al ⁵²	Yes	No	No	No	No	Yes	No	No	No
Monnet et al45	Yes	Yes	Yes	Yes	No	Yes	No	No	No
Monnet et al59	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No
Natalini et al ⁴⁸	Yes	No	No	No	No	No	No	No	No
Perner et al ⁴⁹	No	No	No	No	No	Yes	Yes	No	No
Feissel et al ²¹	No	No	No	No	Yes	No	No	Yes	No
Auler et al ¹⁶	No	No	No	No	Yes	No	No	No	No
Soubrier et al ⁷⁶	Yes	Yes	Yes	Yes	No	No	No	No	No
Osman et al ⁷⁸	g	nd	nd	nd	nd	nd	nd	nd	nd
Monnet et al40	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No
Lamia et al ⁶⁰	Yes	Yes	Yes	Yes	No	No	No	No	No
Maizel et al ⁹	Yes	Yes	No	No	Yes	No	No	No	Yes
Wyffels et al ⁵⁶	Yes	No	No	No	Yes	no	no	No	No
Huang et al ²⁷	nd	nd	Nd	nd	nd	nd	nd	nd	nd
Jabot et al ⁶²	No	No	No	No	No	No	No	Yes	No
Monge Garcia et al ⁶¹	Yes	Yes	No	Yes	nd	No	No	no	No
Vallée et al ⁵³	Yes	Yes	No	Yes	No	No	No	No	No
Vistisen et al ⁵⁵	nd	nd	Nd	nd	nd	nd	nd	nd	nd
Monge Garcia et al ³⁹ Biais et al ⁶³	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	Yes No	No No	no No	No Yes
Mahjoub et al ³⁵	Yes	No	No	No	Yes	Yes	No	No	No
Moretti et al ⁴⁶	No	No	No	No	No	No	No	No	No
Heijmans et al ²⁶	No	No	No	No	Yes	No	No	No	No
Preau et al ⁶⁴	Yes	Yes	Yes	yes	No	No	No	Yes	No
Lakhal et al ¹¹	Yes	Yes	Yes	No	No	Yes	Yes	No	No
Mahjoub et al ⁶⁵	Yes	No	No	No	No	Yes	Yes	No	No
Wyler von Ballmoos et al ⁵⁷	No	No	No	No	Yes	No	No	No	No
Loupec et al ³¹	Yes	Yes	Yes	No	Yes	Yes	No	No	No
Giraud et al ²⁵	Yes	No	No	No	Yes	No	No	No	No
Monnet et al ⁴³	Yes	Yes	Yes	Yes	Yes	No	No	No	No
Machare-Delgado et al ³³	Yes	No	No	No	Yes	Yes	No	No	No
Lakhal et al ¹²	Yes	Yes	Yes	No	No	Yes	Yes	No	No
Muller et al ⁶⁶	No	Yes	No	No	No	Yes	No	No	No
Yazigi et al ⁵⁸	nd	nd	nd	nd	nd	nd	nd	nd	nd
Lakhal et al ¹⁰	Yes	Yes	Yes	No	No	Yes	Yes	No	No
Khwannimit et al ²⁹	Yes	Yes	Yes	Yes	Yes	No	No	No	No
Monnet et al44	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No
Monnet et al ⁷¹	Yes	Yes	Yes	Yes	Yes	No	No	No	No
Muller et al ⁴⁷	Yes	Yes	Yes	Yes	No	No	Yes	No	No
Preau et al ⁶⁸	Yes	Yes	Yes	Yes	No	No	No	No	No
Mahjoub et al ³⁴	Yes	No	No	No	Yes	Yes	Yes	No	No
Monnet et al ⁷⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No
Monge Garcia et al ⁶⁹	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No
Biais et al ¹⁷ Dong et al ⁷⁰	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes No	No Yes	No No	No No	No No
Fellahi et al ⁶⁷				No		No	No		
Fellahi et al ²²	No No	No No	No No	No	Yes Yes	No	No	No No	No No
Suehiro et al ¹⁴	No	No	No	No	No	No	No	No	No
Cecconi et al ¹⁸	No	No	No	No	No	No	No	Yes	Yes
Freitas et al ¹⁵	No	No	No	No	Yes	No	No	Yes	No
Saugel et al ⁷⁵	No	No	No	No	Yes	No	No	No	No
Fischer et al ²⁴	No	No	No	No	Yes	No	No	No	No
Lakhal et al ¹³	Yes	Yes	Yes	No	Yes	Yes	Yes	No	No
Monnet et al ⁴¹	Yes	Yes	Yes	Yes	Yes	No	Yes	No	No
Monnet et al ⁴²	Yes	Yes	Yes	Yes	Yes	No	No	No	No
Kupersztych-Hagege et al ⁷²		Yes	Yes	Yes	Yes	No	Yes	No	No
Monnet et al ⁷³	nd	nd	Nd	nd	yes	nd	nd	no	No

(Continued)

1536 www.anesthesia-analgesia.org Copyright © 2017 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.

ANESTHESIA & ANALGESIA

Table 2. Continue	d								
		Indications for FC							
Authors	Hypotension	Oliguria	Skin Mottling	Tachycardia	Physician Judgment	Need or Reduction of Inotropes or Vasopressors	Lactate Increase	Diagnosis of Sepsis or Septic Shock	Renal or Hepatic Dysfunction
Luzi et al ³²	Yes	Yes	Yes	Yes	No	No	Yes	No	No
Fischer et al ²³	Yes	Yes	Yes	Yes	Yes	No	No	No	No
Marik et al ³⁶	nd	nd	nd	nd	nd	nd	nd	nd	nd
Smorenberg et al ⁵¹	Yes	No	No	No	No	Yes	No	No	No
Hu et al ⁷⁹	Yes	Yes	Yes	No	No	No	Yes	No	No
Ishihara et al ²⁸	Yes	No	No	No	No	No	No	No	No
Charbonneau et al19	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes
Wu et al77	Yes	Yes	Yes	Yes	Yes	No	No	No	No

Hypotension is defined as systolic or mean arterial pressure either below an absolute value, or expressed as percentage of reduction from baseline, or indicated as a generic reduction of blood pressure; oliguria corresponds to a drop in urine output below 0.5 mL/h for at least 2 consecutive hours; tachycardia is characterized by an increase in heart rate above 100 beats/min. Lactate indicates the presence of either generic lactate acidosis or an increase above a predefined cutoff level. The diagnosis of sepsis/septic shock, renal and hepatic dysfunction is done according to the international guidelines available at the time the study was performed. The diagnosis of sepsis/septic shock as inclusion criteria in the study was not considered as indication for FC administration. The "physician judgment" in some studies was just based on subjective decision of the attending physician while in other studies it was based on predefined criteria of hemodynamic instability.

Abbreviations: FC, fluid challenge; nd, not defined.

Indication for the Fluid Challenge

Several clinical, pharmacological, or laboratory indicators of fluid depletion were used to trigger a FC. Hypotension (systolic or mean arterial pressure either below a fixed value or expressed as percent reduction from baseline or a generic reduction of the blood pressure) was used in 48 (67.6%), 9-13,17,19,20,23,25,28,29,31-36,38-45,47,48,50-54,56,59-61,63-65,68-72,74,76,77,79 oliguria (a drop in urine output below 0.5 mL/h for 2 or 3 consecutive hours) in 37 (52.1%), 9-13,17,19,20,23,29,31,32,34,39-45,47,50,53,59-61,63,64,66, 68-72,74,76,77,79 physician judgment in 35 (49.3%), 9,13,15-17,19-26,29,31, 33-35,37,40-44,56,57,59,67,69,71-75,77 clinical evidence of skin mottling

in 33 (46.4%), $^{10,12,13,17,19,20,23,29,31,32,39-45,47,50,59-61,63,64,68-72,74,76,77,79}$ tachycardia, as defined by an increase in heart rate above 100 to 110 beats/min, in 29 (40.8%), $^{17,19,20,23,29,32,39-45,47,50,53,59-61,63,64,}$ $^{68-72,74,76,77}$ need for initiating or reducing administration of vasoactive drugs in 23 (32.3%), $^{10-13,31,33-35,38-40,44,45,49,51,52,54,59,65,66,69,70,74}$ lactate increase in 17 (23.9%), $^{10-13,19,20,32,34,41,44,47,49,50,65,72,74,79}$ diagnosis of sepsis/septic shock in 9 (12.7%), 15,18,19,21,38,50,54,62,64 and renal or hepatic dysfunction in 5 (7.0%) studies (see Table 2). $^{9,18-20,63}$

A safety limit interrupt the FC was used in 4 (5.6%) studies by the same authors. $^{10\mathchar`-13}$

Quantity of Fluid Challenge

In 12 (17%) studies, $^{15,16,19-21,26,46,52-54,58,75}$ the median (IQR) of the mean volume administered was 7 (7–9) mL/kg. Of the remaining 59 (83.1%) studies, 55 (77.5%) infused 500 mL, $^{9-14,17,22-25,27,29-45,47-51,55,56,59-74,76-78}$ 2 (2.8%) 250 mL, 18,28 1 (1.4%) 200 mL, 57 and 1 (1.4%) 300 mL (see Table 3). 79

Type of Fluid Administered

Colloids 44 (62.0%) were used in studies. where 34 (77.3%) infused 6% hydroxyethylsta rch,15,19-24,26,27,29,31,37-39,46-48,50,53-58,61,64,66-70,76,78,79 3 (6.7%) 4% succinyl-gelatine,35,51,52 and 2 (4.5%) 6%49 or 10% Dextran.28 In 5 (11.3%) studies, the type of colloid was unspecified.^{10–13,18} Twenty-six (36.5%) studies9,14,16,17,25,32-34,36,40-45,59,60,62,63,65,71-75,77 used crystalloids and 1 (1.5%) study utilized blood (Table 3).30

Of 6 studies identified in the 2000 to 2004 period, 5 (83.3%) infused colloids and another one (12.5%) blood. Of

27 studies in the 2005–2010 period, 18 (66.6%) used colloids and 9 (33.4%) crystalloids. Of 38 studies in the 2011 to 2014 period, 20 (52.5%) use colloids and 18 (47.5%) crystalloids (Figure 2).

Duration of Fluid Administration

The duration of fluids administration was 30 minutes in 32 studies (45.1%),^{10–15,21,29,32,35,37–39,41,42,44,46,48–51,53,54,61,64,65,68–70,73–75 15 minutes in 15 studies (21.1%),^{9,17,19,22–24,26,30,47,52,60,63,66,67,77} 20 minutes in 11 studies (15.5%),^{16,20,28,34,43,56,58,71,76,78,79 10 minutes in 9 studies (12.7%),^{25,31,33,36,45,57,59,62,72} and in 5,¹⁸ 7.5,⁴⁰ and 90⁵⁵ minutes in one single study (1.4%). Only one study (1.4%) reported the infusion rate (10 mL/kg/h).²⁷ The median (IQR) of the mean rate of infusion, across 58 studies indicating volume and duration of infusion, was 18 (6–67) mL/min (see Table 3).}}

Hemodynamic Response

Overall, the mean (SD) of the mean rate of fluid responders across the studies was 52.0% (13.0%). Forty-four studies (62.0%) assessed fluid responsiveness considering the rate of increase in CI or CO. The positive response was defined by an increase $\geq 15\%$ in 34 studies^{14-16,19-25,27,28,31,38,41-44,46,48,53,55,66,267,69,71-78}; $\geq 10\%$ in 7 studies^{10-13,49,50,79}; $\geq 12\%$ in 2 studies,^{44,59} and $\geq 11\%$ in 1 investigation.⁴⁶ Twenty-two (31.0%) studies utilized either SVI or SV for assessing fluid responsiveness; 15 of these studies considered positive response an increase $\geq 15\%$,^{17,18,29,32,34,35,3} 7,39,58,60,61,63,64,68,70 5 studies $\geq 10\%$,^{33,36,51,52,57} and 2 single studies $\geq 12\%^{65}$ and $\geq 5\%$.²⁶ Five studies (7.0%) used aortic blood flow or aortic velocity-time integrals increase $\geq 15\%$ to identify fluid responsiveness (see Table 3).^{40,45,47,59,66}

Forty-five studies reported the variation of mean (SD) arterial pressure before and after FC, which was higher in responders than in nonresponders ($11.5 \pm 5.4\%$ vs $6.1 \pm 3.9\%$, respectively; *P* < .001).

Subgroup Analysis

Only 2 subgroups of studies enrolled at least 75% of patients with one specific cause of hemodynamic instability, septic (31 studies^{12,15,19–21,27,29,33–35,37,38,41–44,49,50,54,60,62,64–66,68,70–73,76,78}) and

www.anesthesia-analgesia.org 1537

Table 3. Modalities of Fluid Challenge in the Studies Included

varborinfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluioninfluion	Table 3. Modali	ties of F	luid Challeng	ge in the s	Studies li	ncluded				
Author (m) Fuel (m) (m) (m) Vm/m Vm/m No									FC Infusion	
						-	0			
	Authors	(mL)		. ,	(mL/min)	Variable	Device		or Dynamic Indexes	
Failesale at all ²⁰ 6K HES 20 nd CD 215K ECO-TTE 41 No No et all ²⁰ 500 6K HES 30 nd CD 215K ECO-TTE 41 No No Sina et all ²⁰ 500 6K HES 30 16.7 CL > 105 PAC 63 PVC low (IC) No Kammer et all ²⁰ 500 Biod 15 33.3 CO ≥ 12% PAC 63.8 PVC low (IC) No Valide et all ²⁰ 500 Saline 10 50.0 ABF : 158 COTTE 52 No No Valide et all ²⁰ 500 65.4 KB 30 10.7 C1 > 158 FAC 59 No No Valide et all ²⁰ 500 65.4 KB 30 10.7 C1 > 158 FAC 59 No No Valide et all ²⁰ 500 65.7 C1 > 158 ECO-TTE 59 No No Valide et all ²¹ 500 Saline <th< td=""><td>Michard et al³⁸</td><td>500</td><td>6% HES</td><td>30</td><td>16.7</td><td>$CI \ge 15\%$</td><td>PAC</td><td>40</td><td>No</td><td>No</td></th<>	Michard et al ³⁸	500	6% HES	30	16.7	$CI \ge 15\%$	PAC	40	No	No
	Michard et al ³⁷	500	6% HES	30	16.7	SVI >15%	PiCCO	49	No	No
et al ²⁴ Show a tal ²⁷ PAC C3 PVC low (IC) No Valide et al ²⁶ 4/kg 4/kg 4/kg 4/kg 500 Saline 10 500 Saline 10 So0 ABF 1-15% PAC 23.2 No No Monnet et al ²⁶ 500 Saline 10 50.0 ABF 1-15% PAC 47 No No Nationi et al ²⁶ 500 6/k HES 10 1.6.7 C1 > 10% PAC 44 No No Souther et al ²⁶ 500 6/k HES 20 2.5.0 C1 > 15% PAC 43 No No No Souther et al ²⁶ 500 6/k HES 20 2.5.0 C1 > 15% PAC 43 No No No Souther et al ²⁶ 500 6/k HES 10 mL/ nd C2 > 15% PAC 48 No No	Feissel et al ²⁰	8/kg	6% HES	20	nd	CO ≥ 15%	ECO-TTE	41	No	No
500 6% HES 30 16.7 Cl > 10% PAC 63 PVC low (IC) No Valide ct all ²⁴ 4/kg 4% Succ. 15 nd SV) > 10% Cardiol 33.2 No No No Monnet et all ²⁶ 4/kg 4% Succ. 15 nd SV) > 10% Cardiol 33.2 No No No Monnet et all ²⁶ 500 Saline 10 50.0 ABF > 15% ECOTEE 52 No No Presel et all ²⁴ 500 6% HES 30 16.7 Cl > 10% PRC 43 No No Subdier et all ²⁴ 500 6% HES 20 2.50 Cl > 15% PRC 43 No No Subdier et all ²⁴ 500 Saline 15 33.3 SV > 15% ECOTTE 50 No No Subdier et all ²⁶ 500 Saline 15 33.3 SV > 15% ECOTTE 50 No No Monet et all ²⁶ 500 <t< td=""><td>Vieillard-Baron</td><td>10/kg</td><td>6% HES</td><td>30</td><td>nd</td><td>$CI \ge 11\%$</td><td>ECO-TEE</td><td>30</td><td>No</td><td>No</td></t<>	Vieillard-Baron	10/kg	6% HES	30	nd	$CI \ge 11\%$	ECO-TEE	30	No	No
	et al ⁵⁴	, 0								
		500	6% HES	30	16.7	CI > 10%	PAC	63		
Valide ct all ²⁴ 4/kg 4/kg 2/kg 2/kg 2/kg 2/kg 2/kg 2/kg 2/kg 2	1/ 120	500		4.5		00 1 1000	51.0			
		. –					•			
$\begin{split} & \text{Pener et al}^{43} & \text{SO} & eSk PES no n n n n n n n n n n n n n n n n n n$										
		500			16.7					No
Soution Soution Soution Soution Soution Soution Soution No Soution at		8/kg	6% HES						No	
	Auler et al ¹⁶	20/kg	•	r 20	nd	CI ≥ 15%	PAC	66	No	No
	Soubrier et al ⁷⁶	500		20	25.0	Cl > 15%	ECO-TTE	59	No	No
Wyffels et al ⁸⁶ 500 6% HES 20 25.0 Cl ≥ 15% PAC 62 PADP > 18 No Huang et al ⁸⁷ 500 6% HES 10 mL/ kg/h nd Cl ≥ 15% PICCO/PAC 60 No No Jabot et al ⁶³ 500 6% HES 30 16.7 SVI ≥ 15% PICCO 100 No No Vallée et al ⁶³ 500 6% HES 30 16.7 SVI ≥ 15% PICCO 46 No No Vallée et al ⁶³ 6/kg 6% HES 30 16.7 SVI ≥ 15% Viglieo 50 No No Bials et al ⁶³ 500 6% HES 30 16.7 SVI ≥ 15% ECO-TTE / 66.6 PV>12% (IC) No Manjoub et al ⁶⁴ 70 6% HES 30 16.7 SVI ≥ 15% ECO-TTE / 16.6 PV>12% (IC) No Heijmans et al ⁶⁴ 700 6% HES 30 16.7 SVI ≥ 15% ECO-TTE / 16.6 PV=12% (IC) No Heijmans e										
Imm Hg (EC) Huang et al ²⁷ 500 6% HES 10 mL/ hg/h nd Cl ≥ 15% PICC0/PAC 46 No No Jabb et al ⁶² 500 Saline 10 50.0 Cl ≥ 15% PICC0 100 No No No Monge Garcia 500 6% HES 30 nd Cl > 15% PICC0 46 No No No Vistisen et al ⁶⁵ 500 6% HES 30 nd Cl > 15% PICC0 46 No No Vistisen et al ⁶⁵ 500 6% HES 30 nd Cl > 15% PICC0 46 No No Bials et al ⁶⁵ 500 6% HES 30 16.7 SV > 15% ECO-TTE 66. No No Mahjoub et al ⁶⁴ 500 4% Succ. 30 16.7 SV > 15% ECO-TTE 66 PV>12% (IC) No Matrian at al ⁶⁴ 10° HBM 6% HES 30 16.7 SV > 15% ECO-TTE 61 No No Lakhal et al ¹⁴¹ 500 Gelatine<										
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Wyffels et al ⁵⁶	500	6% HES	20	25.0	CI ≥ 15%	PAC	62		No
Jabot et all ⁶² 500 Saline 10 50.0 Cl > 15% PICC0 100 No No Wonge Garcia 500 6% HES 30 10.7 SVI ≥ 15% FloTac 37 No No Vallée et all ⁶³ 6/kg 6% HES 30 nd Cl > 15% PICC0 46 No No Vallée et all ⁶³ 60 6% HES 30 nd Cl > 15% PICC0 46 No No Bias et all ⁶³ 500 6% HES 30 16.7 SVI ≥ 15% Vigileo 50 No No Bias et all ⁶³ 500 4% Succ. 30 16.7 SVI ≥ 5% ECO-TTE / 66.6 No No Mahjoub et all ⁶⁵ 500 4% Succ. 30 nd Cl > 15% FiCO FiC 66.6 No No No Lekhal et all ⁶¹ 7/kg 6% HES 30 nd Cl > 15% FiCO FIC No	Huang et al ²⁷	500	6% HES		nd	$CI \ge 15\%$	PiCCO/PAC	46	- · ·	No
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$										
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Jabot et al ⁶²								No	No
Vallée et al ⁵³ 6/kg 6% HES 30 nd Cl > 15% PICO 46 No No Vistisen et al ⁶⁵ 500 6% HES 90 5.6 Cl > 15% PICO 74 No No Biai et al ⁵³ 500 S/HES 30 16.7 SV ≥ 15% ECO-TTE 66.6 No No Mahjoub et al ⁵⁵ 500 4% Succ. 30 16.7 SV ≥ 15% ECO-TTE 66 PPV>12% (IC) No Moretti et al ⁴⁶ 7.0 6% HES 30 16.7 SV ≥ 15% ECO-TTE 66 PPV>12% (IC) No Moretti et al ⁴⁶ 500 6% HES 30 16.7 SV ≥ 15% ECO-TTE 41 no No Lakhal et al ⁴¹¹ 500 Gelatine 30 16.7 SV ≥ 15% ECO-TTE 41 no No Majoub et al ⁶⁵ 500 Saline 30 16.7 SV ≥ 15% ECO-TTE 41 no No No Lakhal et al ⁴⁵¹ 500 Saline 30 16.7 SV ≥ 15%	Monge Garcia et al ⁶¹	500	6% HES	30	16.7	SVI ≥ 15%	FloTrac	37	No	No
Vistisen et al ⁸⁵ 500 6% HES 90 5.6 Cl > 15% PAC 74 No No No No Monge Garcia 500 6% HES 30 16.7 SV ≥ 15% Vigileo 50 No No No No No No No No Statise et al ⁸³ 500 Saline 15 33.3 SV ≥ 15% ECO-TTE / 66.6 No		6/kg	6% HES	30	nd	CI > 15%	PiCCO	46	No	No
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$										
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Monge Garcia									
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	et al ³³ Biais et al ⁶³	500	Saline	15	33.3	SV ≥ 15%	,	66.6	No	No
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Mahiauh at al35	FOO	10/ 5000	20	167	$C_{\rm V} > 1 E_{\rm V}$		66		No
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$									· · ·	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $. –							, .	
	Heijmans et al ²⁰	10 ↓BIAII	6% HES	15	na	SVI ≥ 5%		51	no	INO
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Preau et al ⁶⁴	500	6% HES	30	16.7	$SV \ge 15\%$	ECO-TTE	41	no	No
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Lakhal et al ¹¹	500	Gelatine	30	16.7	CO > 10%	PiCCO	42	,	<i>'</i>
	Mahioub et al65	500	Saline	30	16.7	SVI > 12%	CARDIOO	51.5		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Wyler von Ballmoos						-			
Giraud et al25500Saline1050.0Cl $\geq 15\%$ PAC47Cl $< 2.2 L/min/m^2$ (IC)No PAOP >18 mm Hg (IC)Monnet et al^43500Saline2025.0Cl $\geq 15\%$ PiCCO62NoNoMachare-Delgado et al^33500Saline1050.0SVI $\geq 10\%$ ECO-TTE32NoNoLakhal et al12500Gelatine3016.7CO $\geq 10\%$ PAC/PiCCO40NoNoMuller et al ⁶⁶ 5006% HES1533.3VTI $\geq 15\%$ ECO-TTE54NoNoYazigi et al ⁵⁸ 7/kg6% HES20ndSVI $\geq 15\%$ PAC68PAOP ≥ 18 mm Hg (EC)NoLakhal et al ¹⁰ 500Gelatine3016.7CO $\geq 10\%$ PiCCO/PAC39EVLWi > 22 mL/kg (EC)Yes PAOP>18 mm Hg (EC)Khwannimit et al ²⁹ 500Saline3016.7CI $> 15\%$ PiCCO/Nexfin42NoNoMonnet et al ⁴⁴ 500Saline3016.7CI $> 15\%$ PiCCO/Nexfin42NoNoMuller et al ⁴⁷ 5006% HES1533.3VTI $\geq 15\%$ ECO-TTE50NoNoMuller et al ⁴⁷⁴ 500Saline2025.0Cl $\geq 15\%$ PiCCO55NoNoMuller et al ⁴⁸ 5006% HES3016.7SV $\geq 15\%$ ECO-TTE50NoNoMonnet et al ⁶⁸ 5006% HES30 </td <td></td> <td>500</td> <td>00/ 1150</td> <td>10</td> <td>50.0</td> <td>00 1 4 5 4</td> <td></td> <td>50.5</td> <td></td> <td></td>		500	00/ 1150	10	50.0	00 1 4 5 4		50.5		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Giraud et al ²⁵									
$ \begin{array}{ c c c c c c c } \mbox{Machare-Delgado} & 500 & Saline & 10 & 50.0 & SVI \geq 10\% & ECO-TTE & 32 & No & No \\ et al^{33} & & & & & & & & & & & & & & & & & & $	Manuat at a1/3	500	Calina	20	05.0		D:000	<u></u>		Nie
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										
	•	500	Saline	10	50.0	SVI ≥ 10%	ECO-ITE	32	No	No
	Lakhal et al ¹²	500	Gelatine	30	16.7	CO ≥ 10%	PAC/PiCCO	40	No	Yes
Yazigi et al 58 7/kg 6% HES 20 nd SVI $\geq 15\%$ PAC 68 PAOP $\geq 18 \text{ mm Hg}$ (EC) No Lakhal et al 500 Gelatine 30 16.7 $CO \geq 10\%$ PiCCO/PAC 39 EVLWi $>22 \text{ mL/kg}$ (EC) Yes Khwannimit 500 6% HES 30 16.7 SVI $\geq 15\%$ FloTrac 57 No No Monnet et al 42 500 Saline 30 16.7 CI $> 15\%$ PiCCO/Nexfin 42 No No Monnet et al 500 Saline 20 25.0 CI $\geq 15\%$ PiCCO 55 No No Muller et al 6% HES 15 33.3 VTI $\geq 15\%$ ECO-TTE 50 No No Preau et al 68 500 6% HES 30 16.7 SV $> 15\%$ ECO-TTE 43.5 No No Mahjoub et al 500 Saline 20 25.0 SV $> 15\%$ ECO-TTE 43.5 No No Mahjoub et al 30 16.7 CI $> 15\%$ <t< td=""><td>Muller et al⁶⁶</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>No</td></t<>	Muller et al ⁶⁶									No
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$										
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Lakhal et al ¹⁰									·
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$						_ 10/3			, .,	,
		500	6% HES	30	16.7	$SVI \ge 15\%$	FloTrac	57		No
		500	Saline	30	16.7	Cl > 15%	PiCCO/Nevfin	42	No	No
Muller et al ⁴⁷ 500 6% HES 15 33.3 VTI \geq 15% ECO-TTE 50 No No Preau et al ⁶⁸ 500 6% HES 30 16.7 SV > 15% ECO-TTE 43.5 No No Mahjoub et al ³⁴ 500 Saline 20 25.0 SV > 15% ECO-TTE 71 No No Monnet et al ⁷⁴ 500 Saline 30 16.7 Cl > 15% PiCCO 46 No No							· ·			
Preau et al ⁶⁸ 500 6% HES 30 16.7 $SV > 15\%$ ECO-TTE 43.5 No No Mahjoub et al ³⁴ 500 Saline 20 25.0 $SV > 15\%$ ECO-TTE 71 No No Monnet et al ⁷⁴ 500 Saline 30 16.7 Cl > 15% PiCCO 46 No No										
Mahjoub et al ³⁴ 500 Saline 20 25.0 SV >15% ECO-TTE 71 No No Monnet et al ⁷⁴ 500 Saline 30 16.7 Cl > 15% PiCCO 46 No No										
Monnet et al ⁷⁴ 500 Saline 30 16.7 Cl > 15% PiCCO 46 No No										
Information with the second state of the seco										
	wonge Garcia et al ³⁹	500	0% HES	30	10.7	00≥15%	CardloQ	57	INU	INO

(Continued)

1538 www.anesthesia-analgesia.org

ANESTHESIA & ANALGESIA

Authors	Volume (mL)	Fluid	Time of Infusion (min)	Rate of infusion (mL/min)	Hemodynamic Variable	Measuring Device	Responders (%)	FC Infusion Triggered by Static or Dynamic Indexes	Safety Limit
Biais et al ¹⁷	500	Saline	15	33.3	$SV \ge 15\%$	ECO-TTE/PRAM	54	No	No
Dong et al ⁷⁰	500	6% HES	30	16.7	$SVI \ge 15\%$	PiCCO	68	No	No
Fellahi et al ⁶⁷	500	6% HES	15	33.3	CI > 15%	PiCCO/ECOM	56	No	No
Fellahi et al ²²	500	6% HES	15	33.3	$CI \ge 15\%$	PiCCO/ECOM	84	No	No
Suehiro et al14	500	Ringer lactate	30	16.7	$CI \ge 15\%$	VIGILEO	47.5	No	No
Cecconi et al18	250	COLLOIDS	5	50.0	SV >15%	LidCO plus	39	No	No
Freitas et al ¹⁵	7/kg	6% HES	30	nd	CO >15%	PAC	48	No	No
Saugel et al ⁷⁵	7/kg	Crystalloids	30	nd	CI ≥15%	PiCCO	29	No	No
Fischer et al ²⁴	500	6% HES	15	33.3	CI>15%	PiCCO	71	No	No
Lakhal et al ¹³	500	Gelatine	30	16.7	CO > 10% (regular rhythm) CO > 15 % (arrhythmia)	PiCCO/PAC	37	EVLWi >22 mL/kg (EC) PAOP>18 mm Hg (EC)) Yes
Monnet et al41	500	Saline	30	16.7	$CI \ge 15\%$	PiCCO	43	No	No
Monnet et al ⁴²	500	Saline	30	16.7	CI >15%	PiCCO2	49	No	No
Kupersztych-Hagege et al ⁷²	500	Saline	10	50.0	CI ≥ 15%	NICOM / PiCCO	39.6	No	No
Monnet et al ⁷³	500	Saline	30	16.7	CI > 15%	PiCCO	52	No	No
Luzi et al ³²	500	Saline	30	16.7	$SV \ge 15\%$	ECO-TTE	59	No	No
Fischer et al ²³	500	6% HES	15	33.3	$CI \ge 15\%$	PiCCO / Nexfin	73	No	No
Marik et al ³⁶	500	Saline	10	50.0	SVI > 10%	NICOM	53	No	No
Smorenberg et al ⁵¹	500	4% Succ.	30	16.7	SVI > 10%	PAC	44	PVC < 10 mm Hg (IC) PAOP < 12 mm Hg (IC)	No)
Hu et al ⁷⁹	300	6% HES	20	15.0	$CI \ge 10\%$	PiCCO	52	No	No
Ishihara et al ²⁸	250	10 % Dextran	20	12.5	CI >15%	PiCCO	53	No	No
Charbonneau et al ¹⁹	7/kg	6% HES	15	nd	$CI \ge 15\%$	ECO-TEE	59	No	No
Wu et al77	500	Crystalloids	15	33.3	CO ≥ 15%	ECO-TTE	54	No	No

PiCCO/PiCCO2; PULSION Medical Systems, Munich, Germany. LidCO plus; LidCO Group PLC, London, UK. NICOM; Cheetah Medical, Portand, OR. Nexfin; BMEYE, Amsterdam, the Netherlands. CardioQ; Deltex Medical Ltd, Chichester, UK. PRAM; Vygon Health, Padua, Italy. FlowTrac; Edwards Lifesciences, Irvine, CA. Abbreviations: ABF, aortic blood flow; BMI, body mass index; CI, cardiac index; CO, cardiac output; CVR central venous pressure; EC, exclusion criteria; ECO-TTE, transthoracic echocardiography; ECO-TEE, transesophageal echocardiography; EVLWi, Extravascular Lung Water Index; 4% Succ, Succinylated gelatine 4%; 6% HES, 6% Hydroxyethylstarch; IC, inclusion criteria; nd, not defined; PAC, pulmonary artery catheter; PAOP pulmonary artery occlusion pressure; PV, pulse pressure

variation; SV, stroke volume; SVI, stroke volume index; VTI, Velocity Time Integral.

postsurgery (16 studies^{16,18,22–24,26,28,30,51,55–58,61,63,67}). The median (IQR) of the mean rate of fluid responders did not differ between the 2 subgroups, 49% (42-49) and 59% (42-70) for septic and postsurgery, respectively (P = .27). Hypotension was the most common criteria for FC administration in both groups, (71.0% and 43.8% of septic and postsurgery subgroups, respectively). Oliguria was the second most used criteria for indicating FC, representing 58.1% and 12.5% of septic and postsurgery subgroup, respectively. Colloids were used in 19 (61.3%) of the 31 studies including predominantly septic patients, and in 13 (86.7%) of 16 studies of the postsurgery subgroup. The mean (SD) of the mean rate of fluid administration was 23.6 (11.2) mL/min in septic and 26.6 (11.9) mL/ min in postsurgery. The median (IQR) of the mean duration of FC administration was 30 minutes (20-30) in septic and 15 minutes (15–20) in postsurgery (P = .02) subgroups.

Assessment of Variables Affecting FC Outcome

Table 4 summarizes the logistic regression analysis assessing the relationship between the primary reasons determining hemodynamic instability (sepsis or postsurgical), presence of oliguria and hypotension (the 2 most common criteria for FC), rate of administration and a positive response rate exceeding the average rate (52%) of responders of the overall studies. We found no correlation between a higher rate of fluid responsiveness and any of these variables.

DISCUSSION

In a systematic review of studies published in the last 20 years on the FC in critically ill adult patients, we found marked variability in the definition, implementation, and assessment of the FC. In the majority of the studies, a 500 cc bolus (most often of colloid) was infused over 30 minutes, without predetermined stopping rules, and $\geq 15\%$ increases in CI or CO were used to assess the result. We also observed that the median time of FC administration and use of oliguria as a criterion for FC, were both more likely in the septic subgroup.

Indication for the Fluid Challenge

The most common criteria for attempting a FC clinical signs such as hypotension (67.6% of studies) and oliguria (52.1% of studies) may not exclusively be the result of fluid depletion. For instance, ICU sedation affects both tachycardia and hypotension.⁸⁰ Also, reduction in urinary output may result from renal dysfunction and thus not necessarily respond to a FC.⁸¹ Importantly, our subgroup analysis found oliguria to be more commonly used as an indication for FC in studies enrolling predominantly septic patients.

About half the patients in the studies we reviewed did not respond to fluid administration, which suggests that using these signs to identify potential fluid responders may not be successful.




Figure 2. Quality of fluid challenge over the years.

Table 4. Relationship Between Rates ofResponders and Patients' Characteristics							
Variables	Studies With Responders ≥ 52%	Studies With Responders < 52%	P Value				
Septic patients, n (%)	10/24 (41.7)	6/23 (26.1)	.26				
Postsurgery	10/34 (29.4)	6/35 (17.1)	.23				

patients, n (%)			
Hypotension, n (%)	24/36 (66.7)	24/36 (66.7)	.80
Oliguria, n (%)	18/36 (50.0)	19/36 (52.7)	1.00
Colloids, n (%)	21/36 (58.3)	23/35 (68.6)	.37
Time of FC	20 (15–30)	30 (15–30)	.07
administration			
(min)			

See text for further explanations.

Abbreviation: FC. fluid challenge.

Abbreviation. FC, nulu challenge.

Static or dynamic physiologic indices were utilized in a minority of studies (16.9%). This frequency is considerably less than the 57.3% reported by the FENICE study.⁸ The association between these indices and clinical signs may improve the selection of patients for FC. However, static indices, particularly central venous pressure are unreliable for fluid response assessment in ICU patients⁸² and pulse pressure variation, the most reliable dynamic index,⁸³ can be properly used only in a small portion of ICU patients in whom all the validity criteria of this dynamic index are satisfied.⁸⁴

Quantity and Duration of Fluid Challenge

In 77.5% of the studies, the FC consisted of 500 mL fluid boluses. Five hundred milliliters was also the median volume FC used in the FENICE study.⁸ In 60.5% of studies, the infusion was administered in 20 or 30 minutes, with a median infusion rate of 18 mL/min, similar to the median 24 minutes and 17 mL/min recently reported by the FENICE study.⁸ Interestingly, the duration of volume administration was shorter in studies with a rate of FC responders \geq 52%, suggesting that a more rapid FC may affect responsiveness. The phase of distribution among different tissue compartments for crystalloids normally takes 25–30 minutes, and the fraction remaining in the plasma is related to both duration and rate of infusion.⁸⁵ Aya et al⁸⁶ recently suggested an even shorter duration, finding that the hemodynamic effect of 250 mL of crystalloids infused over 5 minutes, is dissipated within 10 minutes, in both responders and nonresponders. The hemodynamic effect of colloids is likewise complex, as infusion of the same volume causes a greater plasma expansion in hypovolemic than in nonhypovolemic patients.⁸⁷

Type of Fluid Challenge

Figure 2 lists the type of fluids utilized for the FC throughout between 2000 and 2014. Overall, colloids were used more often than crystalloids. When grouping studies in 3 epochs, however, the ratio between colloids and crystalloids decreased from 5:0 in the 2000–2004 period, to approximately 3:1 in the 2005–2010 period, to approximately 1:1 in the 2011 to 2014 period. In keeping with this trend, a large 2007 cross-sectional study found colloids used more frequently than crystalloids,⁷ whereas in the 2013, FENICE survey crystalloids are more commonly used (74%).⁸

Hemodynamic Response

While in 62.6% of the studies an increase of $\geq 15\%$ of CI or CO immediately after FC completion defined a positive response, in current clinical practice fluid responsiveness is often assessed by an rise in arterial blood pressure.⁸ This metric only reflects an increase in CO in patients with high arterial elastance⁸ and is not reliable when used for passive leg raising test evaluation.⁸⁸ The threshold value of the variable used to assess fluid responsiveness may thus influence the result of a FC for some patients, who may be responders when the threshold for responsiveness is 10% but nonresponders when the threshold is increased to 15%.

CONCLUSIONS

The FC is not well standardized and lacks of consistency among the published studies. The most common form of administration, whose appropriateness remains to be clarified, consists in infusing 500 mL of crystalloid or colloids in 20 or 30 minutes, and assessing whether or not this infusion determines an increase in CI or CO \geq 15%. Defining strict criteria for FC administration and response assessment is deemed necessary for meaningful comparisons of data among studies.

DISCLOSURES

Name: Antonio Messina, MD, PhD. Contribution: This author designed the study, collected the data, performed the data analysis, and wrote the manuscript. Name: Federico Longhini, MD. Contribution: This author helped with data collection, manuscript

preparation, and data interpretation.

Name: Corinne Coppo, MD.

Contribution: This author helped with data collection, manuscript preparation, and data interpretation.

Name: Aline Pagni, MD.

Contribution: This author helped with data collection, manuscript preparation, and data interpretation.

Name: Ramona Lungu, MD.

Contribution: This author helped with data collection, manuscript preparation, and data interpretation.

Name: Chiara Ronco, MD. Contribution: This author helped with data collection, manuscript preparation, and data interpretation.

Name: Marco Ambrogio Cattaneo, MD.

Contribution: This author helped with data collection, manuscript preparation, and data interpretation.

ANESTHESIA & ANALGESIA

Name: Simone Dore, PhD.

Contribution: This author performed data analysis, helped with data interpretation, and manuscript preparation.

Name: Giovanni Sotgiu, MD. **Contribution:** This author performed data analysis, helped with data interpretation, and manuscript preparation.

Name: Paolo Navalesi, MD, FERS

Contribution: This author designed the study, collected the data, performed the data analysis, and wrote the manuscript.

All authors listed on the title page have read the draft, confirmed the validity and legitimacy of the data and its interpretation, approved the final version, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

This manuscript was handled by: Avery Tung, MD, FCCM.

REFERENCES

- Cecconi M, Parsons AK, Rhodes A. What is a fluid challenge? Curr Opin Crit Care. 2011;17:290–295.
- Magder S. Fluid status and fluid responsiveness. Curr Opin Crit Care. 2010;16:289–296.
- 3. Marik PE, Monnet X, Teboul JL. Hemodynamic parameters to guide fluid therapy. *Ann Intensive Care.* 2011;1:1.
- Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369:1726–1734.
- Vincent JL, Weil MH. Fluid challenge revisited. Crit Care Med 2006;34:1333–1337.
- Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med.* 2013;39:165–228.
- Finfer S, Liu B, Taylor C, et al; SAFE TRIPS Investigators. Resuscitation fluid use in critically ill adults: an international crosssectional study in 391 intensive care units. *Crit Care*. 2010;14:R185.
- Cecconi M, Hofer C, Teboul JL, et al; FENICE Investigators; ESICM Trial Group. Fluid challenges in intensive care: the FENICE study: a global inception cohort study. *Intensive Care Med.* 2015;41:1529–1537.
- Maizel J, Airapetian N, Lorne E, Tribouilloy C, Massy Z, Slama M. Diagnosis of central hypovolemia by using passive leg raising. *Intensive Care Med.* 2007;33:1133–1138.
- Lakhal K, Ehrmann S, Benzekri-Lefèvre D, et al. Brachial cuff measurements of blood pressure during passive leg raising for fluid responsiveness prediction. *Ann Fr Anesth Reanim.* 2012;31:e67–e72.
- 11. Lakhal K, Ehrmann S, Runge I, et al. Central venous pressure measurements improve the accuracy of leg raising-induced change in pulse pressure to predict fluid responsiveness. *Intensive Care Med.* 2010;36:940–908.
- Lakhal K, Ehrmann S, Benzekri-Lefèvre D, et al. Respiratory pulse pressure variation fails to predict fluid responsiveness in acute respiratory distress syndrome. *Crit Care*. 2011;15:R85.
- Lakhal K, Ehrmann S, Perrotin D, Wolff M, Boulain T. Fluid challenge: tracking changes in cardiac output with blood pressure monitoring (invasive or non-invasive). *Intensive Care Med.* 2013;39:1953–1962.
- 14. Suehiro K, Rinka H, Ishikawa J, Fuke A, Arimoto H, Miyaichi T. Stroke volume variation as a predictor of fluid responsiveness in patients undergoing airway pressure release ventilation. *Anaesth Intensive Care.* 2012;40:767–772.
- 15. Freitas FG, Bafi AT, Nascente AP, et al. Predictive value of pulse pressure variation for fluid responsiveness in septic patients using lung-protective ventilation strategies. *Br J Anaesth.* 2013;110:402–408.
- Auler JO Jr, Galas F, Hajjar L, Santos L, Carvalho T, Michard F. Online monitoring of pulse pressure variation to guide fluid therapy after cardiac surgery. *Anesth Analg.* 2008;106:1201–1206.
- Biais M, Cottenceau V, Stecken L, et al. Evaluation of stroke volume variations obtained with the pressure recording analytic method. *Crit Care Med.* 2012;40:1186–1191.
- Cecconi M, Monti G, Hamilton MA, et al. Efficacy of functional hemodynamic parameters in predicting fluid responsiveness

with pulse power analysis in surgical patients. *Minerva Anestesiol*. 2012;78:527–533.

- 19. Charbonneau H, Riu B, Faron M, et al. Predicting preload responsiveness using simultaneous recordings of inferior and superior vena cavae diameters. *Crit Care*. 2014;18:473.
- Feissel M, Michard F, Faller JP, Teboul JL. The respiratory variation in inferior vena cava diameter as a guide to fluid therapy. *Intensive Care Med.* 2004;30:1834–1837.
- Feissel M, Teboul JL, Merlani P, Badie J, Faller JP, Bendjelid K. Plethysmographic dynamic indices predict fluid responsiveness in septic ventilated patients. *Intensive Care Med.* 2007;33:993–999.
- Fellahi JL, Fischer MO, Rebet O, Massetti M, Gérard JL, Hanouz JL. A comparison of endotracheal bioimpedance cardiography and transpulmonary thermodilution in cardiac surgery patients. J Cardiothorac Vasc Anesth. 2012;26:217–222.
- Fischer MO, Coucoravas J, Truong J, et al. Assessment of changes in cardiac index and fluid responsiveness: a comparison of Nexfin and transpulmonary thermodilution. *Acta Anaesthesiol Scand*. 2013;57:704–712.
- 24. Fischer MO, Pelissier A, Bohadana D, Gérard JL, Hanouz JL, Fellahi JL. Prediction of responsiveness to an intravenous fluid challenge in patients after cardiac surgery with cardiopulmonary bypass: a comparison between arterial pulse pressure variation and digital plethysmographic variability index. *J Cardiothorac Vasc Anesth.* 2013;27:1087–1093.
- Giraud R, Siegenthaler N, Gayet-Ageron A, Combescure C, Romand JA, Bendjelid K. ScvO(2) as a marker to define fluid responsiveness. *J Trauma*. 2011;70:802–807.
- Heijmans JH, Ganushak YM, Theunissen MS, Maessen JG, Roekaerts PJ. Predictors of cardiac responsiveness to fluid therapy after cardiac surgery. *Acta Anaesthesiol Belg*. 2010;61:151–158.
- Huang CC, Fu JY, Hu HC, et al. Prediction of fluid responsiveness in acute respiratory distress syndrome patients ventilated with low tidal volume and high positive end-expiratory pressure. *Crit Care Med.* 2008;36:2810–2816.
- Ishihara H, Hashiba E, Okawa H, Saito J, Kasai T, Tsubo T. Neither dynamic, static, nor volumetric variables can accurately predict fluid responsiveness early after abdominothoracic esophagectomy. *Perioper Med. (Lond)* 2013;2:3.
- 29. Khwannimit B, Bhurayanontachai R. Prediction of fluid responsiveness in septic shock patients: comparing stroke volume variation by FloTrac/Vigileo and automated pulse pressure variation. *Eur J Anaesthesiol.* 2012;29:64–69.
- Kramer A, Zygun D, Hawes H, Easton P, Ferland A. Pulse pressure variation predicts fluid responsiveness following coronary artery bypass surgery. *Chest.* 2004;126:1563–1568.
- Loupec T, Nanadoumgar H, Frasca D, et al. Pleth variability index predicts fluid responsiveness in critically ill patients. *Crit Care Med.* 2011;39:294–299.
- Luzi A, Marty P, Mari A, et al. Noninvasive assessment of hemodynamic response to a fluid challenge using femoral Doppler in critically ill ventilated patients. J Crit Care. 2013;28:902–907.
- Machare-Delgado E, Decaro M, Marik PE. Inferior vena cava variation compared to pulse contour analysis as predictors of fluid responsiveness: a prospective cohort study. J Intensive Care Med. 2011;26:116–124.
- Mahjoub Y, Benoit-Fallet H, Airapetian N, et al. Improvement of left ventricular relaxation as assessed by tissue Doppler imaging in fluid-responsive critically ill septic patients. *Intensive Care Med.* 2012;38:1461–1470.
- Mahjoub Y, Pila C, Friggeri A, et al. Assessing fluid responsiveness in critically ill patients: False-positive pulse pressure variation is detected by Doppler echocardiographic evaluation of the right ventricle. *Crit Care Med.* 2009;37:2570–2575.
- Marik PE, Levitov A, Young A, Andrews L. The use of bioreactance and carotid Doppler to determine volume responsiveness and blood flow redistribution following passive leg raising in hemodynamically unstable patients. *Chest.* 2013;143:364–370.
- Michard F, Alaya S, Zarka V, Bahloul M, Richard C, Teboul IL. Global end-diastolic volume as an indicator of cardiac preload in patients with septic shock. *Chest.* 2003;124:1900–1908.
- Michard F, Boussat S, Chemla D, et al. Relation between respiratory changes in arterial pulse pressure and fluid responsiveness

November 2017 • Volume 125 • Number 5

www.anesthesia-analgesia.org 1541

Copyright © 2017 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.

in septic patients with acute circulatory failure. *Am J Respir Crit Care Med.* 2000;162:134–138.

- 39. Monge García MI, Gil Cano A, Díaz Monrové JC. Brachial artery peak velocity variation to predict fluid responsiveness in mechanically ventilated patients. *Crit Care*. 2009;13:R142
- 40. Monnet X, Chemla D, Osman D, et al. Measuring aortic diameter improves accuracy of esophageal Doppler in assessing fluid responsiveness. *Crit Care Med.* 2007;35:477–482.
- Monnet X, Guérin L, Jozwiak M, et al. Pleth variability index is a weak predictor of fluid responsiveness in patients receiving norepinephrine. *Br J Anaesth.* 2013;110:207–213.
- 42. Monnet X, Julien F, Ait-Hamou N, et al. Lactate and venoarterial carbon dioxide difference/arterial-venous oxygen difference ratio, but not central venous oxygen saturation, predict increase in oxygen consumption in fluid responders. *Crit Care Med.* 2013;41:1412–1420.
- Monnet X, Letierce A, Hamzaoui O, et al. Arterial pressure allows monitoring the changes in cardiac output induced by volume expansion but not by norepinephrine. *Crit Care Med.* 2011;39:1394–1399.
- 44. Monnet X, Picard F, Lidzborski E, et al. The estimation of cardiac output by the Nexfin device is of poor reliability for tracking the effects of a fluid challenge. *Crit Care*. 2012;16:R212.
- 45. Monnet X, Rienzo M, Osman D, et al. Esophageal Doppler monitoring predicts fluid responsiveness in critically ill ventilated patients. *Intensive Care Med.* 2005;31:1195–1201.
- Moretti R, Pizzi B. Inferior vena cava distensibility as a predictor of fluid responsiveness in patients with subarachnoid hemorrhage. *Neurocrit Care*. 2010;13:3–9.
- 47. Muller L, Bobbia X, Toumi M, et al; AzuRea group. Respiratory variations of inferior vena cava diameter to predict fluid responsiveness in spontaneously breathing patients with acute circulatory failure: need for a cautious use. *Crit Care*. 2012;16:R188.
- Natalini G, Rosano A, Taranto M, Faggian B, Vittorielli E, Bernardini A. Arterial versus plethysmographic dynamic indices to test responsiveness for testing fluid administration in hypotensive patients: a clinical trial. *Anesth Analg.* 2006;103:1478–1484.
- Perner A, Faber T. Stroke volume variation does not predict fluid responsiveness in patients with septic shock on pressure support ventilation. *Acta Anaesthesiol Scand*. 2006;50:1068–1073.
- Silva E, De Backer D, Creteur J, Vincent JL. Effects of fluid challenge on gastric mucosal PCO2 in septic patients. *Intensive Care Med.* 2004;30:423–429.
- Smorenberg A, Lust EJ, Beishuizen A, Meijer JH, Verdaasdonk RM, Groeneveld AB. Systolic time intervals vs invasive predictors of fluid responsiveness after coronary artery bypass surgery. *Eur J Cardiothorac Surg*. 2013;44:891–897.
- Vallée F, Fourcade O, De Soyres O, et al. Stroke output variations calculated by esophageal Doppler is a reliable predictor of fluid response. *Intensive Care Med.* 2005;31:1388–1393.
- Vallée F, Richard JC, Mari A, et al. Pulse pressure variations adjusted by alveolar driving pressure to assess fluid responsiveness. *Intensive Care Med.* 2009;35:1004–1010.
- 54. Vieillard-Baron A, Chergui K, Rabiller A, et al. Superior vena caval collapsibility as a gauge of volume status in ventilated septic patients. *Intensive Care Med.* 2004;30:1734–1739.
- Vistisen ST, Struijk JJ, Larsson A. Automated pre-ejection period variation indexed to tidal volume predicts fluid responsiveness after cardiac surgery. *Acta Anaesthesiol Scand*. 2009;53:534–542.
- Wyffels PA, Durnez PJ, Helderweirt J, Stockman WM, De Kegel D. Ventilation-induced plethysmographic variations predict fluid responsiveness in ventilated postoperative cardiac surgery patients. *Anesth Analg.* 2007;105:448–452.
- Wyler von Ballmoos M, Takala J, Roeck M, et al. Pulse-pressure variation and hemodynamic response in patients with elevated pulmonary artery pressure: a clinical study. *Crit Care*. 2010;14:R111.
- Yazigi A, Khoury E, Hlais S, et al. Pulse pressure variation predicts fluid responsiveness in elderly patients after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2012;26:387–390.
- Monnet X, Rienzo M, Osman D, et al. Passive leg raising predicts fluid responsiveness in the critically ill. *Crit Care Med.* 2006;34:1402–147.

- 60. Lamia B, Ochagavia A, Monnet X, Chemla D, Richard C, Teboul JL. Echocardiographic prediction of volume responsiveness in critically ill patients with spontaneously breathing activity. *Intensive Care Med.* 2007;33:1125–1132.
- Monge García MI, Gil Cano A, Díaz Monrové JC. Arterial pressure changes during the Valsalva maneuver to predict fluid responsiveness in spontaneously breathing patients. *Intensive Care Med.* 2009;35:77–84.
- Jabot J, Teboul JL, Richard C, Monnet X. Passive leg raising for predicting fluid responsiveness: importance of the postural change. *Intensive Care Med.* 2009;35:85–90.
- 63. Biais M, Vidil L, Sarrabay P, Cottenceau V, Revel P, Sztark F. Changes in stroke volume induced by passive leg raising in spontaneously breathing patients: comparison between echocardiography and Vigileo/FloTrac device. *Crit Care*. 2009;13:R195.
- 64. Préau S, Saulnier F, Dewavrin F, Durocher A, Chagnon JL. Passive leg raising is predictive of fluid responsiveness in spontaneously breathing patients with severe sepsis or acute pancreatitis. *Crit Care Med.* 2010;38:819–825.
- 65. Mahjoub Y, Touzeau J, Airapetian N, et al. The passive leg-raising maneuver cannot accurately predict fluid responsiveness in patients with intra-abdominal hypertension. *Crit Care Med*. 2010;38:1824–1829.
- 66. Muller L, Toumi M, Bousquet PJ, et al; AzuRéa Group. An increase in aortic blood flow after an infusion of 100 ml colloid over 1 minute can predict fluid responsiveness: the mini-fluid challenge study. *Anesthesiology*. 2011;115: 541–547.
- 67. Fellahi JL, Fischer MO, Dalbera A, Massetti M, Gérard JL, Hanouz JL. Can endotracheal bioimpedance cardiography assess hemodynamic response to passive leg raising following cardiac surgery? *Ann Intensive Care*. 2012;2:26.
- Préau S, Dewavrin F, Soland V, et al. Hemodynamic changes during a deep inspiration maneuver predict fluid responsiveness in spontaneously breathing patients. *Cardiol Res Pract*. 2012;2012:191807.
- 69. Monge García MI, Gil Cano A, Gracia Romero M, Monterroso Pintado R, Pérez Madueño V, Díaz Monrové JC. Non-invasive assessment of fluid responsiveness by changes in partial endtidal CO2 pressure during a passive leg-raising maneuver. *Ann Intensive Care.* 2012;2:9.
- Dong ZZ, Fang Q, Zheng X, Shi H. Passive leg raising as an indicator of fluid responsiveness in patients with severe sepsis. *World J Emerg Med.* 2012;3:191–196.
- Monnet X, Bleibtreu A, Ferré A, et al. Passive leg-raising and end-expiratory occlusion tests perform better than pulse pressure variation in patients with low respiratory system compliance. *Crit Care Med.* 2012;40:152–157.
- 72. Kupersztych-Hagege E, Teboul JL, Artigas A, et al. Bioreactance is not reliable for estimating cardiac output and the effects of passive leg raising in critically ill patients. *Br J Anaesth*. 2013;111:961–6
- 73. Monnet X, Bataille A, Magalhaes E, et al. End-tidal carbon dioxide is better than arterial pressure for predicting volume responsiveness by the passive leg raising test. *Intensive Care Med.* 2013;39:93–100.
- 74. Monnet X, Dres M, Ferré A, et al. Prediction of fluid responsiveness by a continuous non-invasive assessment of arterial pressure in critically ill patients: comparison with four other dynamic indices. *Br J Anaesth.* 2012;109:330–338.
- 75. Saugel B, Kirsche SV, Hapfelmeier A, et al. Prediction of fluid responsiveness in patients admitted to the medical intensive care unit. *J Crit Care*. 2013;28:537.e1–9.
- 76. Soubrier S, Saulnier F, Hubert H, et al. Can dynamic indicators help the prediction of fluid responsiveness in spontaneously breathing critically ill patients? *Intensive Care Med.* 2007;33:1117–1124.
- 77. Wu Y, Zhou S, Zhou Z, Liu B. A 10-second fluid challenge guided by transthoracic echocardiography can predict fluid responsiveness. *Crit Care*. 2014;18:R108.
- Osman D, Ridel C, Ray P, et al. Cardiac filling pressures are not appropriate to predict hemodynamic response to volume challenge. *Crit Care Med.* 2007;35:64–68.

1542 www.anesthesia-analgesia.org

ANESTHESIA & ANALGESIA

- Hu B, Xiang H, Liang H, et al. Assessment effect of central venous pressure in fluid resuscitation in the patients with shock: a multi-center retrospective research. *Chin Med J. (Engl)* 2013;126:1844–1849.
- Roberts DJ, Haroon B, Hall RI. Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm. *Drugs*. 2012;72:1881–1916.
- Bagshaw SM, Bellomo R, Kellum JA. Oliguria, volume overload, and loop diuretics. Crit Care Med. 2008;36:S172–S178.
- Marik PE, Cavallazzi R. Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. *Crit Care Med.* 2013; 41:1774–1781.
- 83. Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform derived variables and fluid responsiveness

in mechanically ventilated patients: a systematic review of the literature. *Crit Care Med.* 2009;37:2642–2647.

- 84. Mahjoub Y, Lejeune V, Muller L, et al. Evaluation of pulse pressure variation validity criteria in critically ill patients: a prospective observational multicentre point-prevalence study. *Br J Anaesth*. 2014;112:681–685.
- Hahn RG. Volume kinetics for infusion fluids. *Anesthesiology*. 2010;113:470–481.
- Aya HD, Ster IC, Fletcher N, et al. Pharmacodynamic analysis of a fluid challenge. *Crit Care Med.* 2016;44:880–891.
- Chappell D, Jacob M, Hofmann-Kiefer K, Conzen P, Rehm M. A rational approach to perioperative fluid management. *Anesthesiology*. 2008;109:723–740.
- Monnet X, Teboul JL. Passive leg raising: five rules, not a drop of fluid! *Crit Care*. 2015;19:18.